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1 BACKGROUND Marine Compounds 
High diversity and limited resources generate a relentless competition among marine 
habitants. As most sessile marine invertebrates contain only a primitive immune system to 
defend them, these organisms developed an impressive arsenal of chemical weapons 
through millions of years in their everyday fight for survival. These bioactive compounds are 
necessarily highly potent substances, since they become immediately diluted by large 
volumes of sea water. In the last decades, huge efforts were made by both pharmaceutical 
companies and academic institutions, to screen marine biotopes for new compounds that 
may help to battle medical challenges like cancer. This systematic investigation of marine 
environments is reflected in the large number of novel compounds reported in the literature. 
Over 16,000 new marine compounds have been described, patents for the biological activity 
of more than 300 substances were applied for, and over a dozen marine anticancer 
molecules are in different phases of clinical trials (Table III.1). Although, the development of 
marine compounds as therapeutic agents is still in its infancy, as in contrast to terrestrial 
natural products, marine compounds lack an ethno-medical history of several thousand 
years. Thus, marine ecosystems potentially stock new compounds of a non-estimable extent 
which may become clinical relevant (1-4). 
 
Table III.1: Marine Compounds and Analogues in Clinical Trials (3,4) 
Compound Source Target Clinical Phase Company 
Bryostatin Bugula neritina Protein kinase C II solid tumors Aphiosis 
Halichondrin B 
(E7389) 
Halichondria 
okadai Microtubules 
II metastatic breast 
cancer Eisai 
Kahalalide F Bryopsis sp. unknown II in prostate cancer PharmaMar 
Hemiasterlin 
(HTI-286) 
Hemiasterella 
minor Microtubules  II NSCLC Wyeth 
Soblidotin*  Dolabella auricularia Microtubules  I NSCLC 
Daiichi 
Pharmaceuticals 
Cemadotin*  Dolabella auricularia Microtubules  
II NSCLC, breast, lung, 
ovarian cancer 
Knoll Pharmaceutical 
Company 
Synthadotin*  Dolabella 
auricularia 
Microtubules  II NSCLC, prostate 
cancer 
Genzyme 
Corporation 
Didemnins Trididemnum 
solidum 
Palmitoyl 
thioesterase 
II non-Hodgkin’s 
lymphoma 
PharmaMar 
Aplidin Aplidium 
albicans 
Ornithin 
decarboxylase 
II medullary thyroid PharmaMar 
* Dolastatin analogue 
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2 Spongistatin 1 
In the late 1980’s, Pettit et al. extracted a macrocyclic lacton polyether from a dark brown 
sponge of the genius Spongia sp. (Spirastrella spinispirulifera) retrieved in the East Indian 
Ocean. According to its source, it was named spongistatin 1 (5). During the same period of 
time, altohyrtin A was isolated from Hyrtios altum by Kobayashi et al., which revealed to have 
the identical chemical structure (6). Chemists all over the world made notable investments to 
synthesize the complex structure of the molecule, which can now be done within 46 discrete 
steps (7).  
Spongistatin 1 is a tubulin antagonist that binds to β-tubulin at a specific site, and thereby 
destabilizes the microtubules (8). Microtubule-targeting compounds are a wide class of 
strong anticancer compounds. In fact, when spongistatin 1 was tested in NCI (National 
Cancer Institute) panel against human tumor cell lines, it showed strong effects on twenty 
cancer cell lines, including highly aggressive forms like colon carcinoma, melanoma, and 
ovarian carcinoma at remarkably low concentrations (9). In recent studies, spongistatin 1 has 
been demonstrated to be highly effective against a chemotherapy-resistant leukemia cell 
line, whereas peripheral mononuclear blood cells were not significantly affected, indicating 
the therapeutic aptitudes of spongistatin 1 (10). However, besides its initial characterization 
as a tubulin binding agent, reports about the mechanism of action of spongistatin 1 are rare 
and demand for further investigation.  
 
Hyrtios erecta
(Kobajashi M., et al. Tetrahedon Lett, 1993)
Spongia sp. 
(Pettit G.R., et al. J Org Chem, 1993)
 
Figure III.1: Chemical structure of spongistatin 1.  
Spongistatin 1 is a macrocyclic lacton (left panel), isolated from the sponges Spongia sp. and Hyrtios 
erecta (right panel). 
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3 Microtubule-Inhibiting Drugs in Cancer Therapy 
3.1 Chemotherapy and the War on Cancer 
Cancer presents a medical challenge, inflicting the second highest disease-related mortality 
in the Western world, right after cardiovascular diseases (11). Surgical removal of tumors 
and radiotherapy has shown benefit in many cancer types and were even able to cure some 
diseases. But these therapies are restricted to local and regional tumors. Effective treatment 
of patients with advanced or metastatic cancer needs cytotoxic drugs, capable of reaching 
every organ in the body. However, chemotherapy with cytotoxic compounds is often 
accompanied by complications, including severe toxic side effects and the development of 
resistance of cancer cells to chemotherapeutic agents (12). Further, the formation of 
metastases impedes the success of the therapy. Thus for instance, currently only about 5% 
of patients with pancreatic cancer survive 5-years after their initial diagnose (13). At the time 
of diagnose, pancreatic cancer is inoperable in more than 80% of case, since the primary 
tumor typically is in an advanced state and metastases have spread to distant organs (14, 
15). Chemotherapy with the standard therapeuticum gemcitabine has shown no benefit in the 
overall survival. Therefore, investigation of new anticancer drugs is required to improve 
chemotherapy for the inoperable advanced case. 
To reduce toxic-side effects and to improve convalescence, it is important to achieve a 
selectivity of cytotoxic compounds for tumor cells. Cancer cells can be distinguished per 
definition from normal cells: they are characterized by uncontrolled proliferation. Thus, 
targeting the proliferation of cells should repress tumor growth without harming healthy, non-
proliferating cells. The importance of microtubules in mitosis and cell division makes them a 
prime target for anticancer drugs. In view of the success of this class of drugs (Table III.2) it 
has been argued that microtubules represent the best cancer target to be identified so far. 
However, further development of microtubule-targeting compounds is of urgent need, to 
overcome their neurotoxicity and the development of resistances by cancer cells, both of 
which commonly occur with these drugs (16-18).  
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Table III.2 Antimitotic Drugs and Their Stages of Clinical Development (16) 
Binding Site Drug/Analogue Therapeutic Use Clinical Development 
Vinca site Vinblastine Hodgkin’s disease, 
testicular germ-cell cancer 
In clinical use: 22 
combination trials in progress 
 Vincristine Leukemia, lymphomas In clinical use: 108 combination trials in progress 
 Vinorelbine Solid tumors, lymphomas, lung cancer 
In clinical use: 29 Phase I-III 
clinical trials in progress 
 Vinfluvine Bladder, NSCLC, breast 
cancer 
Phase III 
 Cryptophicin 52 Solid tumors Phase II finished 
Colchicine site Combretastatins Potential vascular-targeting agent Phase I, II 
 Methoxybenzene-sulphonamide  Solid tumors Phase I, II 
Taxane site Paclitaxel 
Ovarian, breast and lung 
tumors, Kaposi’s 
carcinoma, trials with 
numerous other tumors 
In clinical use: 207 Phase I-III 
trials in the U.S.  
 Docetaxel Prostate, brain and lung tumors 8 Phase I-III trials in the U.S. 
 Epothilone  Paclitaxel-resistant tumors Phase I-III 
Other sites Estramustine Prostate cancer 
Phase I-III, in numerous 
combinations with taxanes, 
epothilones and Vinca alka. 
 
3.2 Inhibition of Tumor Angiogenesis as an Anticancer Approach 
Besides the classical chemotherapy which targets tumor growth directly by inhibiting tumor 
cell proliferation, the inhibition of pathological angiogenesis as therapeutic approach has 
gained particular importance in cancer treatment (19, 20). As tumors can only grow to a size 
of 1-2 mm3 without being connected to blood vessels to supply them with oxygen and 
nutrients, they secrete endothelial growth factors including VEGF (vascular endothelial 
growth factor) and FGF (fibroblast growth factor) to stimulate vessel growth into the tumor 
tissue. Tumor angiogenesis allows exceeded growth of the tumor and the formation of 
metastases. Some cancer types promote angiogenesis to a very high extent, and are 
extremely difficulty to treat due to their strong vascularization, which optimizes tumor 
progression and metastasis. The inhibition of vessel growth starves the tumor and 
suppresses metastasis, and is therefore an excellent contact point for cancer therapy, 
especially since antiangiogenic therapy targets genetically stable endothelial cells, making 
the development of resistance mechanisms very unlikely (20-22). 
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Similar to cancer cells, endothelial cells have to pass multiple proliferation cycles to form new 
vessels. Thus, it was thought that angiogenesis could be inhibited by the application of cell 
cycle inhibiting compounds, e.g. microtubule-inhibiting drugs (23, 24). In fact, these drugs 
turned out to belong to the most potent antiangiogenic compounds (25-27). Importantly, it 
was reported that the interphase microtubules of endothelial cells are much more sensitive to 
tubulin-targeting agents, than the mitotic microtubules of the spindle apparatus (28). 
Consequently, non-mitotic effects of tubulin-targeting drugs seem to be essential in their 
antiangiogenic action. However, these non-mitotic effects are still poorly characterized, since 
some functions of interphase microtubules are quite cell type-specific and the complexity of 
the effects of microtubule-disassembly in endothelial cells is not understood at all (29, 30). 
 
 
4 Microtubules 
A dense network of filaments is an essential component of the eukaryotic cell, providing the 
cytoplasm structure and stability. These filaments make up the cytoskeleton consisting of 
three main elements: the microfilaments (actin), the microtubules (tubulin), and the 
intermediate filaments (various proteins) (Figure III.2). The functions of the cytoskeleton are 
as multifaceted as its structures are including cellular shaping, scaffolding, cellular 
movement, transport activities, and many more.  
The microtubules are tubes of 24 nm in diameter, and are thereby thicker and more rigid than 
the other cytoskletal structures. They act as scaffolding and are crucial in development and 
maintenance of cell shape, in the transport of vesicles, mitochondria and other components 
through the cell, in cell signaling and in cell division. However, the relevance of microtubules 
for some functions depends particularly on species and cell-type (31, 32). 
nucleus
cytoplasm
cytoplasmic membrane
 
Figure III.2 The cytoskeleton is pervading the cell. 
The cytoplasm is pervaded by a network of filamentous structures, the cytoskeleton. (Source: 
Inside the Cell NIH Pub. No. 05-1051) 
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4.1 The Structure of Microtubules 
4.1.1 The Tubulins 
Microtubules are assembled of tubulins, globular proteins, each of ~55 kDa molecular weight 
and 4 nm length. They exist in several isotypic forms, at least 14 tubulin isotypes that are 
expressed in a variety of tissue specific manners have been identified (33). The α- and the β-
tubulin dimerize into tubulin heterodimers. A third species of tubulins, the γ-tubulin, is only 
located in centrosomes. The α- and the β-monomers are highly conserved and can be found 
in every eukaryotic organism. Although not found in prokaryotes, bacteria express the FtsZ-
protein, a GTPase which is essential in the cell division, with homology in structure and 
function to the tubulins in eukaryotes, underlining the fundamental role of these proteins 
through all phyla (34).  
 
4.1.2 Protofilaments 
The interactions between the α- and the β-tubulins are very stable in the heterodimers, and 
typically the monomers do not dissociate from each other under normal conditions. Thus, the 
heterodimer is the smallest subunit of microtubules. By head to tail attachment, tubulin-
heterodimers are forming the protofilaments, which assemble laterally and generate a tube: 
the microtubule (Figure III.3). The length of microtubules can vary from nanometers up to 
several hundred micrometers. The head-tail arrangement of the heterodimers in the 
protofilaments diposes the polarity of a microtubule: all protofilaments have the same polarity 
and thus there are only α-tubulins at the minus end and only β-tubulins at the plus end of the 
microtubule. The exact alignment of the protofilaments in a tube is not clear yet. They apear 
to be slightly shifted, so that α- and β-tubulin form spirals. The majority of microtubules in a 
cell have the typical singlet structure consisting of 13 protofilaments (Figure III.3 C), whereas 
duplet and triplet structures can only be found in specialized microtubule-structures like cilia 
or centrosomes (31, 32, 34).  
 
III INTRODUCTION 
 11 
α-tubulin
β-tubulin
protofilament
+ end
- end
A B C
singlet
duplet
triplet
 
Figure III.3 The structure of microtubules. 
(A) α- and β-tubulins dimerize to tubulin heterodimers, which assemble to protofilaments. (B) 
Protofilaments are forming the microtubule, displaying a polarity with α-tubulins at the plus end 
(+ end) and β-tubulins at the minus end (- end). (C) Oversight: the typical cytoplasmic 
microtubule is organized in the singlet structure consisting of 13 protofilaments. Duplet and 
tripet structures can be only found in the centrosome and the basal body. 
 
4.2 Organization of Microtubules 
The regulation of microtubule-assembly in the cell is very complex: growing, shrinking, and 
stable microtubules can be found in the same cell. Further, a single microtubule can switch 
between assembly and disassembly. This highly dynamic behavior of microtubule growth 
and collapse is called ‘dynamic instability’, and is regulated by the MTOC (microtubule-
organizing center) and by MAPs (microtubule-associated proteins). 
 
4.2.1 The MTOC 
MTOCs are specialized structures in the cell, which nucleate microtubule polymerization by 
binding and stabilizing the minus end of microtubules. The MTOC consists of a right angled 
pair of centriols, which are assembled of microtubule triplets in a windmill-like configuration. 
The centriols are positioned in the center of a MTOC, but they do not contact the microtubule 
minus end directly. In contrast, γ-tubulin and pericentrin, two further proteins located in the 
MTOC, are supposed to interact with the microtubule minus end, since the assembly of 
microtubules can be completely suppressed by employing inhibitory antibodies against one 
of these proteins. 
MTOCs exert different functions in the cell and have different terms due to their functions. 
During the interphase, there is only one single MTOC, the centrosome. It is located near the 
nucleus and organizes all cytoplasm pervading microtubules (Figure III.4). The centrosome 
doubles in the early phase of mitosis, moves to opposite poles of the nucleus and forms the 
spindle poles. The spindle poles nucleate the astral and the mitotic microtubules in the 
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mitotic spindle apparatus. The basal body is a MTOC structure, organizing the microtubules 
in flagella and cilia. Besides, the basal body and associated motorproteins are generating the 
driving forces of flagella and cilia movements (35-37).  
 
+ end
- end
- end
- end
+ end
+ end
A B
nucleus
 
Figure III.4 The centrosome nucleates microtubule-assembly in the cell. 
(A) Two pairs of centriols (in blue-green) are in the center of the centrosome, each consisting of 
9 triplet microtubules. During interphase, the centrosome is located near the nucleus and 
promotes microtubule-assembly by stabilizing their minus ends. (B) In GFP-tubulin transfected 
endothelial cells, the location of the centrosome can be perceived near the nucleus (bright 
signal). Outgoing from this point, microtubules (green) extend to the cell periphery. 
 
4.2.2 The Dynamics of Microtubules 
Microtubules exert many different functions and microtubule dynamics is critical for them. 
Permanent microtubules can be found in cilia and flagella, or in the axons of neurons, as 
microtubules have stabilizing and scaffolding functions. In contrast, microtubule-formation is 
transient during highly dynamic processes, like the assembly and disassembly of the mitotic 
spindle in proliferating cells or the microtubule re-organization during migration (31, 32). 
A critical factor in microtubule-stability is the GTP-binding status of the tubulins. One 
molecule GTP is reversibly bound at the molecule surface of the β-subunit of the 
heterodimer. It can be hydrolyzed to GDP, which in turn can be replaced by GTP. 
Stabilization of the minus end by the MTOC facilitates microtubule growth, but only 
heterodimers with a GTP bound to β-tubulin are incorporated into a growing microtubule. 
During maturation of the microtubule, GTP is hydrolyzed to GDP. Thus a ‘GTP cap’ is 
generated at the plus end, which is a major factor for the stability of microtubules: whenever 
GTP-bound tubulin molecules are added more rapidly than GTP is hydrolyzed, the 
microtubule will retain the GTP cap at its plus end and growth will continue. When the rate of 
polymerization decreases, the GTP cap at the plus converts of to a GDP cap, resulting in 
instability and the disassembly of microtubules (Figure III.5) (35, 37-39).  
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Figure III.5 GTP binding to tubulin is crucial for the microtubule stability. 
Growing microtubules incorporate tubulin heterodimers with GTP bound to the β-subunit at the 
plus end. In the course of time, GTP is hydrolyzed to GDP. If hydrolysis is faster than the 
incorporation of new GTP-tubulin dimers, the GTP cap is lost and the microtubule disassembles 
(catastrophe). The shrinkage of the microtubules can be reversed upon increased assembly of 
GTP tubulin to the plus end (rescue).  
 
Additionally, an ever-increasing number of MAPs regulate the dynamics of microtubules. One 
class of MAPs binds to more mature sections of microtubules, and mediate both stabilization 
and destabilization of the microtubule. A second class of microtubule-interacting proteins, 
including CLIP170, EB1/3, and APC, preferentially binds to the plus end of the microtubule 
and is therefore called +TIPs. These proteins control microtubule plus end dynamics and 
anchor microtubules to the cell cortex. The latter function is a crucial factor in vesicle 
transport and chemotactic migration (37, 40, 41). 
 
4.3 Functions of Microtubules 
4.3.1 The Mitotic Spindle 
The spindle apparatus assembles during mitosis and separates the chromosomes into the 
daughter cells. During early prophase, interphase microtubules are disassembled and the 
centrosom is doubled, forming the spindle poles, which nucleate astral and mitotic 
microtubules. In the meantime, the chromosomes are arranged in the metaphase plate of the 
spindle, with the sister chromatids pointing to opposite end of the spindle. Mitotic 
microtubules extend to the chromosomes and bind to the kinetochore proteins at the 
centromers (Figure III.6). After kinetochor capture, pole bodies induce microtubule shortening 
and sister chromatids are pulled apart to the opposite sites of spindle poles (31, 32). 
However, prior to chromatid-separation, the cell cycle has to pass the spindle assembly 
checkpoint. Thus, if microtubules are not connected properly to centrosomes, the transition 
to anaphase is delayed. A prolonged delay in cell cycle progression in turn results in the 
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initiation of apoptosis. Thus, therapeutic tubulin antagonists are directly interfering with 
mitotic spindle assembly, and thereby induce apoptosis in proliferating cells (42, 43). 
 
BA
 
Figure III.6 The mitotic spindle. 
(A) The assembly of the mitotic spindle apparatus (adopted from The Mc Graw-Hill Company). 
(B) Picture of the mitotic spindle in a GFP-tubulin transfected endothelial cell. Interphase 
microtubules are disassembled and the only polymer microtubule-structures in the cell are the 
astral and the mitotic (kinetochor and polar) microtubules of the spindle. 
 
4.3.2 Cellular Transport 
Cellular transport processes, including the arrangement of organelles and the translocation 
of endosomal vesicles, are largely microtubule-dependent. Since microtubules are organized 
into single arrays with their minus ends associated with the MTOC near the nucleus, and with 
their plus ends located toward the cell’s periphery near the plasma membrane (cortical sites), 
a defined polarity is established. This polarity is utilized by microtubule-associated motor 
proteins to move cargo along the microtubules. The cell also uses actin filaments as a 
transport system. Since actin fibers are significantly shorter than microtubules, they have 
been suggested to bridge the gap between different microtubule arrays at the cell cortex 
(44). 
The microtubule-dependent motor proteins can be divided into two classes: the kinesins and 
the dynamins. The different properties of the two motors are crucial for the regulation of 
transports. Kinesins move in plus end direction and are responsible for the main part of 
exocytosis (secretion) (45), whereas dyneins move predominantly in minus end direction, 
achieving endocytosis, transcytose, and vesicle transport between the ER (endoplasmatic 
reticulum), cis-Golgi, and trans-Golgi (46). Traffic jams on the microtubules are avoided by 
the different nature of kinesin and dynein movement. Kinesins are strong, progressive 
motors, with low tendency for side or back steps. In contrast, dyneins show only poor 
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processivity and the long and flexible stalks of dyneins allow a certain degree of 
maneuverability. Thus, strong walking kinesins force dyneins to give right-of way (47). 
Not only vesicles, but also organelles, the Golgi and mitochondria, are arranged along 
microtubules. These organelles express different surface proteins that are recognized and 
bound by dyneins and kinesins. During migration, the re-arrangement of the Golgi apparatus 
towards the leading edge is of particular importance, as it keeps lipid and protein supply 
coming to cell front (40, 44, 48). Besides the arrangement and the transport of organelles 
and vesicles, microtubules are reported to participate in signaling pathways by translocation 
of protein complexes. However, these processes are very cell-type specific. 
 
 
5 Microtubule-Binding Compounds 
A large number of chemically diverse compounds bind to soluble tubulin or directly to 
tubulins in the microtubule, and thereby interfere with microtubule-stability and dynamics. 
The role of microtubule-binding compounds in cancer therapy was discussed previously     
(III 3 Microtubule-Inhibiting Drugs in Cancer Therapy). 
 
Three major binding sites on the heterodimers are characterized:  
  1.) the taxene binding site  
  2.) the colchicine binding site 
  3.) the Vinca alkaloide binding site.  
 
Tubulin antagonists binding to the taxene-site, like paclitaxel, have only poor affinity for 
soluble tubulin and are rather binding to β-tubulin on the inside surface of a microtubule. This 
binding stabilizes the microtubules, interrupts the microtubule-dynamics and increases the 
polymerization of microtubules at higher concentration of the compound. In contrast, 
compounds which bind to the colchicine site preferentially bind to soluble tubulins, forming a 
poorly reversible colchicinoid-tubulin complex. Incorporation of this complex in the 
microtubule causes the inhibition of its dynamics at low concentration and the disassembly of 
the microtubule at high concentration, since the colchicinoid-tubulin complex cause the loss 
of the GTP cap. Interestingly, most compounds which bind to the colchicine site have turned 
out to be only barely applicable in cancer therapy due to their strong cytotoxic side-effects, 
which might be a consequence of the irreversibility of the colchicinoid-tubulin complex 
formation. Most prominent compounds binding to the colchicine-site are CA4P 
(combretastatin A4 phosphate) and nocodazole. Vinblastine and related compounds bind to 
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the so called Vinca-domain on the β-subunit of the heterodimers. The Vinca alkaloids bind 
rapidly and reversibly to soluble tubulin, as well as to the extreme ends of polymerized 
microtubules with high affinity. Similar to drugs binding to the colchicine site, the binding of a 
compound to the Vinca-domain inhibits microtubule-dynamics at low concentration and 
causes the disassembly of microtubules at high concentration. Other than the compounds 
binding to one of these three tubulin sites, several substances including spongistatin 1 are 
known to bind to tubulin at neither of the presented sites. Their action on microtubule-stability 
and dynamics are quite unique and might provide new properties, allocating them for 
therapeutic approach (49, 50). 
 
 
6 Tumor Angiogenesis 
Angiogenesis is the physiological process of developing new blood vessels from pre-existing 
ones. The term of angiogenesis must be distinguished from ‘vasculogenesis’, the 
spontaneous formation of new blood vessels out of endothelial stem cells (angioblasts), and 
from ‘arteriogenesis’, which is characterized by the formation of medium-sized vessels 
possessing tunica media and tunica adventitia. Angiogenesis in the narrower sense 
describes the formation of thin-walled vessels that can be associated with smooth muscle 
cells and pericytes.  
 
The process of angiogenesis can be divided into distinct steps (Figure III.7) (51):  
  1.) endothelial activation and proliferation 
  2.) chemotactic orientation and migration 
  3.) the formation of a new lumen 
 
Angiogenesis can be primarily observed during embryogenesis, whereas in adults, vessel 
formation is quite inactive and only takes place in wound healing, ovulation or menstruation. 
In the last decades, it was revealed that pathological angiogenesis plays a key role in a 
variety of diseases, like diabetes, rheumatoid arthritis, proliferative retinopathies or cancer 
(20). The process of angiogenesis has been only descriptive for a long time. Only recently, 
research is revealing the molecular mechanisms underlying angiogenesis. These findings 
offer new targets for therapeutic tools and furthermore, allow understanding the mechanisms 
of antiangiogenic compounds that have been well described but not well characterized, e.g. 
the mechanisms of microtubule-inhibiting drugs (52). 
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Figure III.7 Angiogenesis. 
The physiological process of angiogenesis can be separated into distinct steps. (1) Tumor cells 
activate and stimulate endothelial proliferation by secretion of endothelial growth factors. (2) 
Endothelial cells migrate directional to the growth factor gradient and (3) form tubes. Finally, the 
newly established vessels pervade the tumor tissue and supply tumor cells with oxygen and 
nutrients. 
 
6.1 Initiation of Angiogenesis: Endothelial Proliferation 
6.1.1 Hypoxia-Induced Expression of VEGF  
Tumor cells are rapidly proliferating cells with a corresponding demand of nutrients and 
oxygen. The strong metabolic activity of tumor cells causes a permanently hypoxic 
environment. The most important transcription factor of cell’s response to oxygen availability 
is HIF-1 (hypoxia inducible factor 1). HIF-1 controls the expression of a variety of proteins, 
which play crucial roles in the acute and chronic adaptation to oxygen deficiency, including 
the expression of VEGF. HIF-1 is a heterodimer, consisting of two subunits: HIF-1α and   
HIF-1β. The later is constitutively expressed, whereas the protein level of HIF-1α is highly 
regulated in an oxygen-dependent manner. Hypoxic conditions allow the formation of the 
HIF-1α/HIF-1β heterodimer, which induces the expression of VEGF. The growth factor is 
secreted into the extracellular space, diffuses to neighbored blood vessels and initiate 
angiogenesis, by binding to the VEGFR2 (VEGF-receptor 2) on endothelial cells (53). Upon 
binding to its receptor on the endothelium, VEGF induces signaling cascades, which promote 
survival, proliferation, and directional migration. The most prominent cellular pathways 
transducing VEGFR2-activation are AKT, MAPK (ERK) and PKC signaling pathways. 
In fact, there are several growth factors expressed by tumor cells, binding to a plurality of 
endothelial receptors, regulating angiogenesis in many different ways. However, VEGF and 
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its binding to VEGFR2 on endothelial cells are the most important factors promoting tumor 
angiogenesis. 
 
6.1.2 The AKT and the ERK Pathways 
AKT, also known as Protein kinase B, is a 57 kDa serine/threonine kinase and represents a 
central node in proliferation and survival signaling. AKT has three domains: the PH - domain 
(pleckstrin-homology domain), the kinase domain, and the C-terminal tail. 
 
Kinase DomainPH Domain C-Tail
T308 S473
 
Figure III.8 Domain structure of AKT. 
The PH-Domain binds to PIP3 at the cytoplasm membrane. PDK1 interacts with the C-tail and 
phosphorylates T308. The S-residues at position 473 is phosphorylated by PDK2. 
Phosphorylation at both sites recovers full kinase activity of the AKT kinase domain. 
 
Only when the threonine-residue at position 308 (T308) and the serine-residue at position 
473 (S473) are both phosphorylated, AKT is activated. These phosphorylation events 
depend on VEGFR2-activation. After binding to a growth factor, the receptor induces 
activation of the receptor-associated PI3K (Phosphoinositide 3-kinases), which in turn 
phosphorylates the second messenger PI(3,4)P2 to PI(3,4,5)P3. PI(3,4,5)P3 is the binding 
substrate for PH-domains, and binding to PI(3,4,5)P3 recruits AKT to the close neighborhood 
of the membrane-associated kinases PDK1 and PDK2, which then can phosphorylate AKT at 
T308 and S473 (Figure III.9). Being phosphorylated, AKT is released to the cytoplasm, 
where it activates a large number of substrates by phosphorylation (54, 55). Most of AKT 
substrates are involved in survival, cell cycle progression, glucose metabolism, and protein 
synthesis, which are essential processes in proliferation (56). Further, activation of AKT is 
involved in generation and maintenance of cell polarity and migration (57). In this context, 
AKT knock-out cells have been shown to be decreased in proliferation, and impaired in 
migratory and extracellular matrix response (58). 
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MAPKs (Mitogen-activated protein kinases) are serine/threonine-specific kinases that 
respond to extracellular stimuli and regulate various cellular activities, such as gene 
expression, mitosis, differentiation, and cell survival. Proteins of the MAPK-cascade are 
organized in multi-protein complexes that are scaffolded by specific proteins with binding 
domains for multiple proteins. The proteins in those complexes can be composed in different 
constellations, depending on the scaffolding protein. The most important MAPK during 
angiogenesis is ERK1/2 (extracellular-signal regulated kinase 1/2), also known as MAPK 
p42/p44. Activation of VEGFR2 triggers a cascade that converts Ras-GDP to Ras-GTP and 
results in ERK activation by the phosphorylation of two critical residues in the activation loop. 
Activated ERK is released from the multi protein complex, scaffold by KSR (kinase 
suppressor of Ras), and phosphorylates more than 70 substrates, both nuclear and non-
nuclear proteins, which promote cell proliferation and migration (Figure III.9) (59-61). 
 
 
Figure III.9 VEGFR2 activates AKT and ERK signaling. 
The binding of VEGF induces autophosphorylation of the cytoplasmic domain of VEGFR2. This 
phosphorylation promotes the activation of the AKT and the ERK pathway. AKT is 
phosphorylated and activated by PDK1/2 in a PIP3-dependent manner. The activation of ERK is 
taking place after VEGFR2-mediated activation of Raf. Raf phosphorylates MEK, which in turn 
phosphorylates ERK1/2. The ERK phosphorylation chain is facilitated by the scaffold protein 
KSR. 
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6.1.3 The PKC pathway 
The Protein Kinase C-family is a family of serine/threonine protein kinases, consisting of at 
least 10 members, which are divided into three groups: the conventional PKCs (cPKC) α, βI, 
βII, and γ, the novel PKCs (nPKC) δ, ε, η/L, θ and the atypical PKCs (aPKC) ι/λ, and ζ. The 
cPKC and the nPKC are both activated by translocation to the membrane, where they bind 
DAG (diacylglycerol) and undergo conformational changes. In addition, cPKC-activation 
depends both on the release of Ca2+ and on translocation to the membrane (62, 63). PKC α, 
δ, and ε, are known to be involved especially in angiogenic processes (64-66). The binding of 
growth factors to their receptors can activate PLCγ (Phospholipase Cγ), which is a central 
enzyme in cellular signaling, since it generates the second messengers PI3 and DAG by 
hydrolysis of PI(3,4)P2. The binding of PI3 to Ca
2+-channels results in a Ca2+-influx, thus both 
activators of cPKCs, Ca2+ and DAG, are present upon PLC activation, initiating PKC-
signaling cascades.   
 
Figure III.10 Activation of PKC. 
The VEGF-induced activation and autophosphorylation of VEGFR2 activate PLCγ, which 
cleaves the second messenger PI(3,4)P2 into DAG and PI3. PKCs bind to DAG in the 
membrane and take conformational changes. Additionally, PI3 promote Ca
2+ release from the 
ER (endoplasmatic reticulum). Binding of Ca2+ to PKC is necessary for full activation. 
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6.2 Endothelial Migration 
6.2.1 Matrix metalloproteinases 
During angiogenesis, proteolytic activities are required to degrade the basement membrane 
of endothelial cells allowing the invasion into the tissue. Moreover, this process includes the 
removal of obstructing matrix proteins and the creation of space in the matrix for the 
generation of endothelial cell tubes. MMPs (matrix metalloproteinases) are the most 
prominent proteases involved in the remodeling of the extracellular matrix. Especially MMP-2 
and MMP-9 are important during invasive processes, since these proteases are basal 
lamina-degrading enzymes and thus, are able to degrade the basement membrane. The 
promoter regions of MMP genes are very complex, containing multiple consensus sequences 
for different trasncription factors. Thus, it could be shown that endothelial growth factors 
VEGF and FGF both induce the expression of MMPs, but the responsible signaling cascades 
remain to be elucidated (67-69). 
 
6.2.2 Tip Cells and Stalk Cells 
In sprouting vessels, two types of endothelial cells can be identified. Upon a pro-angiogenic 
stimulus (e.g. VEGF), the so-called tip cell is the first cell to emerge from the parent vessel 
and to lead the sprout into the tissue. A tip cell is characterized by distinct properties: it does 
not proliferate, but it is highly migratory, expressing numerous filopodia and lamellopodia that 
search the surrounding tissue for growth factors. Thus, the tip cell functions as motile guide 
that dynamically extends filopodia to explore attractive or repulsive signals that are present in 
the tissue environment. The tip cell is tailing the stalk cells, which have fewer filopodia and 
lamellopodia but undergo cell divisions. These cells form the new vessel lumen. It was 
recently found that the signaling of Notch/Dll4 regulates this differentiation of endothelial cells 
(51, 70, 71).  
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6.2.3 Molecular Processes during Migration 
The process of endothelial migration can be divided into three basic steps: 
  1.) polarization of the cell 
  2.) formation of protrusion and adhesions 
  3.) the retraction of the rear.  
 
The polarization of the endothelial cell is the key step of migration. Cell polarity and its 
maintenance depend on interlinked positive feedback loops, involving small Rho GTPases, 
PI3K, microtubules and vesicular transport. Upon a growth factor stimulus, PI3K rapidly 
accumulate at the leading edge, generating the second messenger PI(3,4,5)P3. PI(3,4,5)P3 
can be dephosphorylated and thus inactivated by the phosphatase PTEN. However, PI3K-
dependent activation of the small Rho GTPase Cdc42 at the leading edge restricts the 
localization of PTEN to the sides and the rear, thereby generating a polarized accumulation 
of second messengers at the front of the cell. Further, Cdc42 regulates the reorientation of 
the MTOC towards the leading edge. In the course, the Golgi apparatus is brought in 
position, keeping supply for the protrusion coming. 
The second messenger PI(3,4,5)P3 activates signaling pathways, including the AKT-
pathway, which induce the formation of protrusion by activation of the small Rho GTPase 
Rac1 with restriction to the leading edge. Rac1 and microtubules polymerization activate 
each other in a reciprocal manner, resulting in F-actin polymerization in the leading edge. 
Accumulation of F-actin at the front generates protrusions that are stabilized by the formation 
of new focal adhesions. 
At the rear, adhesions are disassembled in dependency on FAK/Src/ERK-pathway and 
RhoA. Besides, RhoA regulates the activity of myosin II and therewith the generation of 
tractional forces by F-actin in concert with myosin II motor proteins, which are driving the cell 
forward (for review see (72, 73)). 
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Figure III.11 Cell migration is divided into three distinct steps. 
(A) Cell polarization (B) Formation of protrusions and adhesions (C) Disassembly of adhesions 
and retraction of the rear. Cdc42 mediates polarization by capturing microtubules at the leading 
edge and re-orientating the MTOC. Rac1 promotes actin polymerization in the leading edge and 
therewith the formation of the protrusion. RhoA mediates the disassembly of the adhesions in 
the rear. Further, the contraction of the actin fibers at the sides is regulated by RhoA (adapted 
from A.J. Ridley et al. (72)) 
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6.3 Vessel Formation  
In advanced angiogenesis, endothelial cells assemble as solid cords that subsequently 
acquire a lumen. However, angiogenesis is not completed until smooth muscle cells and 
pericytes are sheathing the newly developed vessel, providing stability and protection. 
Moreover, smooth muscle cells, pericytes, and the basal membrane of the intima mediate 
survival signals that prevent endothelial cells to undergo apoptosis. Once assembled in new 
vessels, endothelial cells become quiescent and survive for years (52, 53).  
However, the physiology of pathological angiogenesis shows differences from normal vessel 
sprouting by formation of a deregulated, chaotic vessel system with enlarged, leaky vessels 
that are only restricted capable in meeting oxygen supplying demands. Moreover, endothelial 
cells are multilayered, and protrude extensions bridging and splitting vessels, contain inter- 
and intracellular holes, show uncontrolled permeability and undergo constant remodeling. 
This seems to be a consequence of uncontrolled and spatially uncoordinated release of 
endothelial growth factors by the tumor cells (52, 53).  
 
endothelial cellssmooth muscle cells
vessel lumen
 
Figure III.12 Vessel formation completes angiogenesis. 
The formation of new vessels is not complete until smooth muscle cells and pericytes are 
assembled around the endothelium, providing stability, protection and pro-survival signalings. 
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7 Aims of the Work 
 
Based on the pronounced efficacy of the marine compound spongistatin 1 against some 
cancer cell lines in vitro, it was aim of the present work to investigate its anticancer activity on 
pancreatic tumor progression and metastasis in vivo. Besides this classical anticancer 
approach, it was also the aim to elaborate the antiangiogenic profile of spongistatin 1. In this 
context, investigation of the underlying mechanisms of the antiangiogenic action of 
spongistatin 1 was supposed to give information not only about spongistatin 1 effects, but 
also about the general action of tubulin antagonism in angiogenesis. 
 
 
IV. MATERIALS AND METHODS 
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1 Materials 
1.1 Compounds 
Spongistatin 1 and CA4P were donated by George R. Pettit (Cancer Research Institute, 
Tempe, AZ, USA). Paclitaxel was purchased from Sigma (Taufkirchen, Germany), 
vinblastine from HEXAL (Holzkirchen, Germany), and staurosporine from Cayman Chemicals 
(Ann Arbor, MI, USA). 
 
1.2 Biochemicals, Inhibitors, Dyes, and Cell Culture Reagents 
  
Accustain® formaldehyde Sigma-Aldrich, Taufkrichen, Germany 
Bradford ReagentTM Bio-Rad, Munich, Germany 
CellTiter BlueTM Promega, Madison, WI, USA 
Collagen A Biochrome AG, Berlin, Germany 
Collagen G Biochrome AG, Berlin, Germany 
Collagenase G Biochrome AG, Berlin, Germany 
Complete® Roche diagnostics, Penzberg, Germany 
DMEM PAN Biotech, Aidenbach, Germany 
Endothelial Growth Medium Provitro, Berlin, Germany 
FCS gold PAN Biotech, Aidenbach, Germany 
M199 Medium  PAN Biotech, Aidenbach, Germany 
MatrigelTM BD Discovery Labware, Bedford, MA, USA 
MitoTracker Mitochondrion-Selective Probes 
Non-essential amino acids  
Invitrogen, Karlsruhe, Germany  
PAA Laboratories, Cölbe, Germany 
Page RulerTM Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Penicillin 
Propidium iodide 
PAN Biotech, Aidenbach, Germany 
Sigma-Aldrich, Taufkirchen, Germany 
PermaFluor mounting medium Beckman Coulter, Krefeld, Germany 
PMA  Sigma, Taufkirchen, Germany 
Pyruvate Merck, Darmstadt, Germany 
Rhodamin-phalloidin Invitrogen, Karlsruhe, Germany 
RNAlater Ambion, Austin, TX, USA 
Streptomycin PAN Biotech, Aidenbach, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Vybrant Cell-Labeling Solution Invitrogen, Karlsruhe, Germany 
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Trypsin/EDTA (T/E)  PBS (+) 
Trypsin 0.50 g  NaCl   7.20 g 
EDTA 0.20 g  Na2HPO4   1.48 g 
PBS ad 1.0 l  KH2PO4   0.43 g 
H2O ad 1.0 l, pH 7.4  (MgCl2 x 6 H2O   0.10 g) 
   (CaCl2 x 2 H2O   0.10 g) 
   H2O ad 1.0 l, pH 7.4 
 
1.3 Technical Equipment 
Name Device  Producer 
AB7300 RT-PCR Real-time PCR system Applied Biosystems,  
   Fosterer City, CA, USA 
Axiovert 200 Inverted microscope Zeiss, Jena, Germany 
Curix 60 Tabletop film processor Agfa, Cologne, Germany 
Custom-made            
   climate chamber 
Life-cell observation on  
   LSM 510 Meta 
EMBLEM,  
   Heidelberg, Germany 
Cyclone Storage Phosphor Screens Canberra-Packard,  
   Schwadorf, Austria 
FACSCalibur Flow cytometer Becton Dickinson, 
Heidelberg, Germany 
FastPrep Homogenizer MP Bio, Illkirch, France 
LSM 510 Meta Confocal laser scanning microscope Zeiss, Jena, Germany 
Mikro 22R Table centrifuge Hettich 
Nucleofector II Electroporation device Amaxa, Cologne, Gemrany 
Odyssey 2.1 Infrared Imaging System  LI-COR Biosciences, 
   Lincoln, NE, USA 
Optima TLXTM Ultracentrifuge Beckman Coulter  
   Krefeld, Germany 
Polytron PT1200 Ultrax homogenizer Kinematica AG, Lucerne, 
Switzerland 
Potter S Homogenizer Braun Biotech GmbH,  
   Mesungen, Germany 
SpectraFluor PlusTM Microplate multifunction reader Tecan,  
   Männedorf, Switzerland 
SunriseTM Microplate absorbance reader Tecan,  
   Männedorf, Switzerland 
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2 Cell Culture 
2.1 HUVEC Isolation and Cultivation 
Primary HUVECs were isolated by collagenase treatment of umbilical cords (74) and used at 
third passage. Cells were cultivated on 0.001% Collagen G-coated flasks or plates in 
Endothelial Growth Medium, containing 10% inactivated FCS and growth factors        (FGF 
1.0 ng/ml, Heparin 0.004 ml/ml, and EGF 0.1 ng/ml). M199 medium was used as starvation 
medium, and M199 medium supplemented with 10% FCS as stopping medium. 
For splitting and seeding (1:3), cells were washed once with pre-warmed PBS, which was 
removed completely with a sterile pipette. 3 ml T/E was added (75 cm2 flask), and cells were 
incubated for 1-2 minutes at 37°C. The digest was terminated by adding approximately 20 ml 
stopping medium. Next, cells were centrifuged for 5 minutes at   1,000 rpm to remove the 
T/E. The supernatant was discarded and the cells were resuspended in pre-warmed 
Endothelial Growth Medium and seeded into flasks or well plates (coated with Collagen G). 
 
2.2 L3.6pl Cultivation 
For in vitro analysis of spongistatin 1 effects on pancreatic cancer, the human pancreatic 
cancer cell line L3.6pl was kindly provided by Christiane J. Bruns (Department of Surgery, 
Klinikum Großhadern, LMU Munich, Germany). The cells were cultivated on 0,001% 
Collagen G-coated culture flasks and stimulation plates in DMEM (Dulbecco's Modified Eagle 
Medium), supplemented with 10% FCS, 1x non-essential amino acids, and 1 mM pyruvate.  
For splitting and stimulation, cells were treated according to the treatment of HUVECs. In 
contrast to HUVECs, L3.6pl needed approximately 5 minutes of incubation in T/E to detach 
from the flask, and the reaction was stopped by adding about 20 ml of L3.6pl culture 
medium. Then cells were centrifuged, resuspended in fresh culture medium, and seeded for 
further cultivation or experiments. As L3.6pl cells are extremely rapid growing cells, they 
were diluted 1:10 upon splitting.  
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3 Flow Cytometry 
 
HFS Buffer 
Na3-citrate 0.1% 
Triton-X 100 0.1% 
PBS ad 1 ml 
   
FACS Buffer  
NaCl 8.12 g 
KH2PO4 0.26 g 
Na2HPO4 2.35 g 
KCl 0.28 g 
Na2EDTA 0.36 g 
LiCl 0.43 g 
Na-azide 0.20 g 
H2O ad 1.0 l, pH 7.37 
    
3.1 Stimulation and Harvest 
75,000 HUVECs per well were seeded into 12-well-plates, allowed to incubate over night at 
37°C, followed by stimulation for 24 hours with various concentrations of spongistatin 1, 
vinblastine, CA4P, and paclitaxel. Cells were washed, trypsinized, resuspended in the 
supernatant, and centrifuged 10 minutes 600x g at 4°C. After another wash with PBS, cells 
were resuspended in HFS-buffer containing 2 mg/ml propidium iodide, and incubated 
protected from light at least 30 minutes at 4°C. The fluorescence of propidium iodide was 
detected by flow cytometry.  
 
3.2 Cell Cycle Analysis 
The fluorescence intensity was measured in the logarithmic mode of the fluorescence 
channel 2 (FL2, λem 585 nm) using a flow cytometer. Intercalating into the DNA-helix, 
propidium iodide-fluorescence depends on the status of cellular chromatin. Under control 
conditions, most cells are in the G0/G1 cell cycle phase with 2n chromosome set, lacking the 
sister chromatids. Cells in the G2/M-phase are in the process of cell division, meaning they 
possess the normal 2n chromosome set as well as the duplicate sister chromatids. This 
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duplication allows the G2/M-phase to be differentiated from the G0/G1-phase due to the 
higher fluorescence peak from the increased amount of propidium iodide intercalation. 
HUVECs in the S-phase are in the synthesis-phase, in which the cytosol is accreted and 
chromatids become duplicated. Hence, the fluorescence peak of S-phase cells is located 
between the fluorescence peaks of G0/G1- and G2/M-phase. In contrast, the DNA is 
fragmented in apoptotic cells and apoptotic bodies, generating a peak which is located left of 
the G0/G1 fluorescence. Regions were set on each fluorescence peak of the four enumerated 
chromatin states, and cells of each region were quantified and set into relation of the total 
cell number. 
 
 
4 Cell Viability Measurements 
Cell viability under spongistatin 1-treatment was measured via reduction of resazurin to 
resorufin (CellTiter-BlueTM) by endothelial cells. 5,000 (proliferating) and 15,000 (confluent) 
HUVEC per 96-well were seeded and stimulated with spongistatin 1 for 24 hours. The assay 
was performed as described in the provided protocol of CellTiter-BlueTM Cell Viability Assay. 
Fluorescence (excitation 530 nm, emission 595 nm) was measured with SpectraFluor Plus 
plate reader. 
 
Figure IV.1 Conversion of resazurin to resorufin. 
 
 
5 Microscopy 
5.1 Immunohistochemistry 
Cells were seeded either on collagen A-coated glass slides, or on ibi-Treat µ-slides (IBIDI, 
Martinsried, Germany). After stimulation, cells were washed once with ice-cold PBS+ and 
fixed in 4% formaldehyde (Accustain®, Sigma-Aldrich, Taufkrichen, Germany) for               
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10-15 minutes. After one PBS washing step, cells were permeabilized by incubating cells in 
0.2% Triton X-100 in PBS for exactly 2 minutes. Then, cells were washed three times for 5 
minutes with PBS, blocked for 15 minutes in 0.2% BSA in PBS, and incubated with the 
primary antibody against Cdc42 (Santa-Cruz Biotechnology Inc., 1:200 in 0.2% BSA/PBS) for 
45-60 minutes. After three washes with PBS for 5 minutes, cells were incubated with light-
protection for 30-60 minutes with the Alexa Fluor 546-conjugated secondary antibody 
(Invitrogen, 1:400 in 0.2% BSA/PBS). Afterwards, cells were washed again three times with 
PBS, and covered with PermaFluor mounting medium for confocal microscopy. 
 
5.2 Live-Cell Imaging 
5.2.1 Mitochondria Staining 
Mitochondrion staining was performed by adding 50 nM MitoTracker Red Cmx Ros to the 
medium. After 15 minutes of dye-uptake, 1.0 nM spongistatin 1 was added (MitoTracker 
remained in the medium) and mitochondria arrangement was documented by live-cell 
imaging (Axiovert 200). 
 
5.2.2 Visualization of Membrane Traffic 
Documentation of membrane trafficking was done by staining HUVECs with the membrane-
staining dye VYBRANT Cell-Labeling solution. Cells were either left untreated, or pre-
incubated with 2.0 nM spongistatin 1 for 3 hours, then the dye was added to the medium   
(15 minutes, 5 µl/ml). Cells were washed and live cell-imaging (LSM 510 Meta) was done in 
endothelial growth medium over a period of 5 hours.  
 
5.2.3 Expression of Recombinant Proteins 
Plasmids were amplified in the E.coli strain DH5α and purificated by using the EndoFree 
Plasmid Maxi Kit (Qiagen GmbH, Hilden, Germany). Procedures were done according to the 
provided protocol. HUVECs were transfected with 7 µg endotoxin-free purified pEGFP-C1-
tubulin (kindly given by Stefan Linder). Transfection was done by electroporation in the 
Nucleofector II, according to the protocol given with the HUVEC Nucleofector Kit (Amaxa). At 
days 2 and 3 after transfection, cells were stimulated with 2.0 nM spongistatin 1 and placed 
into a costumized live-cell observation chamber mounted to the confocal microscope. A time 
series was collected with images taken every 5 minutes for 16 hours. Images were analyzed 
by the LSM Image Browser (Zeiss). 
IV MATERIALS AND METHODS 
 33 
6 Protein Sample Preparations 
6.1 Total Cell Lysates 
 
RIPA Buffer (store at 4°C)  
Tris/HCl 0.79 g 
NaCl 0.87 g 
Nonidet NP 40 1.0 ml 
Deoxycholic acid 0.25 g 
SDS 0.10 g 
Complete® 1:25 
PMSF 1.0 mM 
Na3VO4 1.0 mM 
NaF 1.0 mM 
H2O ad 100 ml 
 
 
5x SDS-Sample Buffer (store at -20° C) 
Tris/HCl 3.125 M, pH 6.8 
Glycerol 10 ml 
SDS 5% 
DTT 2% 
Pryonin Y 0.025% 
H2O ad 20 ml 
 
For Western blot analysis, cells were washed with ice-cold PBS after stimulation. The PBS 
was removed completely and cells were lysed by adding RIPA buffer and freezing at -80° C. 
Cells were thawed on ice, scratched from the plate/dish and transferred to 1.5 ml reaction 
tubes. Cellular debris was removed by centrifugation for 10 minutes at 10.000x g and 4° C. 
Supernatants were transferred to a new reaction tube, and aliquots were taken for protein 
quantification (IV 7.1 Protein Quantification). 5x SDS-sample buffer was added to the lysates, 
and lysates were boiled for 5 minutes at 95° C for inactivation. Protein samples were stored 
at -20°C until use. 
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6.2 Microtubule Fractionation 
 
PIPES Buffer  
PIPES 0.1 M, pH 6.9 
Glycerol 2.0 M 
Triton X-100 0.5% 
MgCl2 2.0 mM 
K-EGTA 2.0 mM 
Paclitaxel 5.0 µM 
GTP 1.0 mM 
PMSF 1.0 mM 
Complete 1:25 
 
 
Ca2+ Buffer  
Tris/HCl 0.1 M, pH 6.8 
MgCl2 1.0 mM 
CaCl2 10 mM 
PMSF 1.0 mM 
Complete  
 
HUVECs were stimulated with spongistatin 1 or paclitaxel, washed twice with ice cold PBS 
and lysed 20 minutes at room-temperature in PIPES buffer. Lysates were centrifuged 45 
minutes at 100,000x g, 4° C. The supernatants were collected (fraction of soluble tubulin), 
while the sediments were incubated one hour at 4° C with 40 µl of Ca2+ buffer. Insoluble 
debris was removed by centrifugation, 10.000x g for 10 minutes at 4° C, to obtain a clear 
fraction of PIPES-insoluble tubulin. Both fractions were boiled 5 minutes in 5x SDS-sample 
buffer (IV 6.1 Total Cell Lysates) for immunoblotting. 
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6.3 Membrane Fractionation 
 
Membrane Lysing Buffer  
Tris/HCl 0.05 M, pH 7.5 
EDTA   0.5 mM 
EGTA   0.5 mM 
DTT   2.0 mM 
Glutathione   7.0 mM 
Glycerol     10% 
Complete®       1:25 
PMSF   1.0 mM 
 
To investigate PKC translocation, HUVEC lysates were separated into a soluble (cytosolic) 
and a particulate (membranous) fraction, as described previously by Li H et al. (75). HUVECs 
were either pre-incubated with 5.0 nM spongistatin 1 prior to stimulation with 10 nM PMA, or 
stimulated with 10 nM PMA alone, washed twice with ice-cold PBS, and homogenized in 
lysing buffer. Lysates were centrifuged at 100.000x g for 1 hour. The supernatant (cytosolic 
fraction) was collected, the pellet washed in lysing buffer containing 1.0 M NaCl, and 
centrifuged at 100.000x g for 30 minutes. The supernatant was discarded, and the pellet was 
solubilized with lysing buffer containing 20 mM CHAPS at 4° C for 30 minutes. After 
centrifugation at 100.000x g for 1 hour, the supernatant was kept as membranous fraction. 
Both fractions were used for Western blotting.  
 
6.4 Protein Isolation of Tissue Sections 
60-80 mg of RNAlater-stored tissue was homogenized 15 seconds in 600 µl RIPA-buffer    
(IV 6.1 Total Cell Lysates) using the Potter S homogenizer. Lysates were centrifuged at 
14.000 rpm and 4° C for 15 minutes. The clear supernatants were boiled in 5x SDS-sample 
buffer (IV 6.1 Total Cell Lysates). Protein concentration was determined using the Bradford 
assay (IV 7.1 Protein Quantification). 
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7 Western Blot Transfer 
7.1 Protein Quantification 
Protein samples were quantified according to Bradford (76). The calibration curve was 
generated by using samples containing defined concentrations of BSA in H2O (50 µg/ml – 
500 µg/ml). 190 µl Bradford reagents (diluted 1:5 in H2O) were added to each 10 µl aliquot of 
1:10 (in H2O) diluted protein samples and calibration samples in an ELISA-plate. All 
measurements were performed in duplicate. Probes were incubated for 5-10 minutes and the 
absorbance was measured in the SunriseTM ELISA reader.  
 
7.2 SDS-PAGE 
 
Electrophoresis Buffer 
Tris base      3.0 g 
Glycine    14.4 g 
SDS      1.0 g 
H2O ad 1.0 l 
 
Stacking Gel  Separating Gel (10%) 
PAA solution 30% 1.275 ml  PAA solution 30%   5.0 ml 
1.25 M Tris/HCl, pH 6.8   0.75 ml  1.5 M Tris/HCl, pH 8.8 3.75 ml 
10% SDS      75 µl  10% SDS  150 µl 
H2O   5.25 ml  H2O   6.1 ml 
APS      75 µl  APS    75 µl 
TEMED      20 µl  TEMED     20µl 
 
SDS-PAGE according to Laemmli (77) was performed by using the Mini Protean III system 
from Bio-Rad (Munich, Germany). Prior to loading the samples, the apparatus was 
assembled as described by the producer, and the chamber was filled with ice-cold 
electrophoresis buffer. 
Protein concentrations of the probes were unified, by adding required volume of 1x SDS-
sample buffer. Then probes were boiled for 5 minutes at 95° C before loading the samples 
on the SDS-Gel. Empty slots were filled with an appropriate volume of 1x SDS-sample 
buffer. To estimate the molecular weights of the separated proteins, 2 µl of the marker Page 
RulerTM Prestained Protein Ladder was additionally loaded on the gel.  
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Proteins were separated in a discontinuous electrophoresis: proteins were focused by 
running the probes through the stacking gel, pH 6.8, (100 V, 20 minutes), and then separated 
in the separating gel, pH 8.8 (200 V, 45 minutes). 
 
7.3 Tank-Blotting 
 
5x Tank Buffer  1x Tank Buffer 
Tris base 15.2 g  5x Tank buffer 200 ml 
Glycin 72.9 g  Methanol 200 ml 
H2O ad 1.0 l  H2O ad 1.0 l 
 
After separating in the SDS-PAGE, proteins were transferred to a nitrocellulose membrane 
(Hybond-ECLTM, Amersham Bioscience, Freiburg, Germany) via tank blotting. A blotting 
sandwich was prepared in a box filled with 1x Tank Buffer to avoid bubbles as follows: 
cathode – pad – blotting paper – separating gel (from SDS-PAGE) – nitrocellulose 
membrane – blotting paper – pad – anode (Figure IV.2). Pads, papers, and membrane were 
equilibrated with 1x Tank buffer 15 minutes prior to running the tank blot. Sandwiches were 
mounted in the Mini Trans-Blot® system (Bio-Rad, Munich, Germany), ice-cold 1x Tank buffer 
filled the chamber and a cooling pack was inserted to avoid excessive heat. Transfers were 
carried out at 4° C, either at 100 V for 90 minutes or at   23 V overnight (especially for high-
molecular weight proteins).  
 
Figure IV.2 Tank blot assembly. 
(Adopted from Bio-Rad, Munich, Germany) 
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7.4 Detection 
 
 
 
After the transfer, sandwiches were disassembled, gels were stained in Coomassie              
(I 7.5 Staining Gels and Membranes), and membranes were washed in 1x TBS-T. Unspecific 
binding reactions were blocked by incubating membranes for at least 2 hours in 5% BSA or 
5% Blotto, each in PBS. After one washing step with 1x TBS-T, membranes were incubated 
with the primary antibody dilution over night at 4° C. The next day, membranes were washed 
3-times with 1x TBS-T, prior to incubation with the secondary antibody. Secondary antibodies 
were incubated protected from light for 1 hour at room-temperature (infrared dye-conjugated 
antibodies) and 2 hours at room-temperature (peroxidase-conjugated antibodies), 
respectively. 
 
7.4.1 Enhanced Chemiluminescence 
Proteins were detected with ECL (enhanced chemiluminescence) when the secondary 
antibody was conjugated to HRP (horseradish peroxidase). Membranes were washed three 
times for 5 minutes with TBS-T after incubation with the secondary antibody. Then the 
membrane was shaken protected from light in ECL PlusTM Western Blotting detection reagent 
(Amersham Bioscience) for 1 minute, and layered between two plastic sheets afterwards. 
Chemiluminescence was detected by exposing the membranes to an X-ray film for the 
appropriate time period in a darkroom. X-ray films were developed in a table processor.  
 
7.4.2 LI-COR 
The detection of protein levels was performed with the Odyssey Infrared Imaging System 
version 2.1 when the secondary antibody was conjugated to an infrared dye (AlexaFluor 680 
or IR-Dye 800). Membranes were washed three times with TBS-T after incubation with the 
secondary antibody and one time with PBS to remove the interfering Tween 20. After 
washing, membranes were scanned and analyzed, and proteins were quantified using the 
Odyssey system software. 
TBS-T  
Tris base 3.0 g 
NaCl 11.1 g 
Tween 20 1.0 ml 
H2O ad 1.0 l 
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Table IV.1: Primary Antibodies 
Antigen  Isotype Dilution Provider Detection 
β-Actin goat 1:1,000 Santa Cruz LI-COR 
AKT rabbit 1:1,000 Cell Signaling LI-COR 
p-AKT T308 rabbit 1:500 Cell Signaling ECL 
p-AKT S473 mouse 1:1,000 Cell Signaling LI-COR 
ERK 1/2 rabbit 1:1,000 Cell Signaling LI-COR 
p-ERK 1/2 T202/Y204 mouse 1:1,000 Cell Signaling LI-COR 
HIF-1α mouse 1:250 BD Transduction  ECL 
MMP-2 rabbit 1:1,000 Cell Signaling LI-COR /ECL 
MMP-9 rabbit 1:1,000 Sigma LI-COR 
PKCα rabbit 1:1,000 Santa Cruz LI-COR 
PKCβ mouse 1:500 BD Transduction ECL 
PKCδ rabbit 1:1,000 Santa Cruz LI-COR 
PKCε rabbit 1:1,000 Santa Cruz LI-COR 
PKCη rabbit 1:1,000 Santa Cruz LI-COR 
PKCθ rabbit 1:1,000 Santa Cruz LI-COR 
PKCζ rabbit 1:1,000 Santa Cruz LI-COR 
p-serine PKC substrates rabbit 1:1,000 Cell Signaling ECL 
β-Tubulin mouse 1:500 Santa Cruz LI-COR 
VE-Cadherin rabbit 1:1,000 Cell Signaling LI-COR 
 
 
Table IV.2: Secondary Antibodies 
Antigen  Conjugate Dilution Provider 
Goat anti:rabbit  HRP 1:1,000 Dianova 
Goat anti:mouse HRP 1:1,000 Santa Cruz 
Goat anti:mouse AlexaFluor 680 1: 10,000 Invitrogen 
Donkey anti:goat AlexaFluor 680 1: 10,000 Invitrogen 
Goat anti:rabbit IR-Dye 800 1: 10,000 Rockland 
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7.5 Staining Gels and Membranes 
 
Coomassie Staining Solution  Coomassie Destaining Solution 
Coomassie blue 3.0 g    
Glacial acetic acid 100 ml  Glacial acetic acid 100 ml 
Ethanol 450 ml  Ethanol 333 ml 
H2O ad 1.0 l  H2O ad 1.0 l 
 
To control equal loading of the gel and the performance of the transfer, polyacrylamide gels 
were stained for 30 minutes with Coomassie-blue, and destained with destaining solution. 
After protein detection, membranes were stained with Ponceau S (0.2% Ponceau S in 5% 
acetic acid) for 5 minutes, and destained with distilled water. 
 
 
8 Kinome Array (PepChip) 
To address the question, which effects tubulin-inhibiting drugs have on overall signaling in 
endothelial cell, a kinome array (PepChip) was performed. The array was done in 
collaboration with Dr. Jos Joore from Pepscan System BV, Lelystad, The Netherlands. 
HUVECs in 4x 100 mm dishes for each treatment group were grown to confluency. 
Untreated cells and cells stimulated with spongistatin 1 (5.0 nM, 30 minutes), vinblastine 
(10.0 nM, 30 minutes), or CA4P (20.0 nM, 30 minutes) were washed twice with ice-cold PBS, 
and lysed with M-PER Mammalian Protein Extraction Reagent (Pierce, Rockford, IL), 
containing 2.5 mM Na4-pyrophosphate, 2 mM Na2-β-glycerophosphate, 1 mM Na3VO4, and 1 
mM NaF. Lysates were centrifuged for 10 minutes at 13,000 rpm, 4° C, and supernatants 
were frozen immediately in liquid nitrogen. PepChip performance and analysis of the results 
were done by Pepscan Presto BV (Lelystad, The Netherlands). On the chip 1,152 different 
peptides with best possible specific phosphorylation motifs for upstream kinases were 
spotted in triplicates (78). Native protein lysates of HUVECs incubated on PepChip with      
[γ-33P] ATP. A radiosensitive screen determined and quantified the phosphorylation status of 
peptides (? kinase substrates), which gave information about the activity of the associated 
upstream kinase. 
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9 PKC In Vitro Assay 
Potential inhibition of PKC isozymes in vitro by spongistatin 1 was assessed using a micellar 
based assay. 150 ng recombinant GST-tagged PKC isozymes α, βI, βII, δ, ε or ζ (kindly 
provided by Dr. M. Kubbutat, ProQinase Ltd, Freiburg, Germany) were incubated in a buffer 
containing 20 mM Tris-HCl, pH 7.5 and 20 mM MgCl2, with 50 µM PKC-α-19-31/Ser25 
substrate peptide (NeoMPS, Strasbourg, France), 1 mM CaCl2, 10 µM phosphatidylserine 
(Sigma), 1 µM 12-O-tetradecanoylphorbol-13-acetate (Sigma), 40 µM ATP and 1 µCi γ-33ATP 
(PerkinElmer, Fremont, CA; 3000 Ci/mM) per 100 µl as previously described (79). In the 
assays for PKCδ and ε CaCl2, and for PKCζ CaCl2, phosphatidylserine and                   
12-O-tetradecanoylphorbol-13-acetate were omitted. Samples containing 50-100 nM of 
spongistatin 1 were compared to controls. The samples were incubated for 10 min. at 30°C 
and subsequently loaded onto phosphocellulose filter disks (Whatman, Dassel, Germany). 
The membranes were washed three times with 1.5% phosphoric acid and twice with distilled 
water. 2 ml of scintillation fluid (Ultima Gold, PerkinElmer) was added to each filter disk and 
radioactivity was counted with a liquid scintillation counter. Two independent experiments in 
which triplicate samples were taken within each experiment were performed. 
 
 
10 Angiogenic In Vitro Assays 
10.1 Proliferation Assay 
1,500 HUVECs were seeded in 96-well-plates and stimulated the next day. Control cells 
were fixed to determine the initial cell number. After 72 hours of stimulation, cells were fixed 
and stained with crystal-violet solution (0.5% crystal violet in 20% methanol) for 10 minutes, 
washed, and air dried. Crystal violet was eluted with 0.1 M sodium citrate in 50% ethanol, 
and the absorbance was measured at 550 nm with the SUNRISETM plate reader.  
 
10.2 Migration Assay 
HUVECs were seeded in 24-well-plates and grown to confluency. The cell monolayer was 
scratched with a pipette-tip (generating a wound of approximately 1 mm), washed and 
incubated over night. Analysis of the wound closure was done by light microscopy using the 
Axiovert 200 microscope and Imago-QE camera system (Till Photonics, Graefelfing, 
Germany). For quantification, the migration tool of S.CORE online imaging analysis (S.CO 
LifeScience, Munich, Germany) was used.  
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For actin staining, HUVECs were seeded on 0.1% Collagen A-coated glass coverslips. The 
confluent monolayer was wounded again with a pipette-tip, washed and stimulated for 6 
hours. Cells were washed with PBS, fixed in 4% formaldehyde for 15 minutes, and 
permeabilized with 0.2% Triton X-100 in PBS. After three washes with PBS, cells were 
stained with rhodamine-conjugated phalloidin for 45 minutes. Another three washes later, 
coverslips were mounted in PermaFluor mounting medium. Visualization and imaging was 
done using the confocal microscope LSM 510 Meta. 
 
10.3 Chemotaxis Assay 
Measurement of the chemotaxis of spongistatin 1-stimulated HUVECs were done using ‘µ-
slides Chemotaxis’ (IBIDI, Martinsried, Germany). A HUVEC suspension of 5x106 cells per 
ml was seeded as described in the ‘µ-slide Chemotaxis’ protocol provided. The upper 
reservoir of the slides contained Endothelial Growth Medium with 10% FCS; the lower 
reservoir contained medium M199 without FCS, generating a FCS-gradient from 0 to 10% 
FCS over the seeded HUVECs (Figure IV.3 A). Chemotaxis was observed over 24 hours by 
live-cell imaging. A time series was collected containing 1 picture every 10 minutes. Cell 
tracking and analysis was done using the manual tracking plug-in (Fabrice Cordelieres) and 
the ‘Chemotaxis and Migration Tool’ (IBIDI) for ImageJ (NIH, Bethesda, MD), as described in 
µ-slide Chemotaxis protocol (Figure IV.3 B). 
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Figure IV.3 The chemotaxis assay on µ-slides. 
(A) Design of the chemotaxis slides. (B) Calculation of endothelial cell movement and directionality. 
 
10.4 Tube Formation Assay 
MatrigelTM was filled into the lower chambers of ‘µ-slide Angiogenesis’ wells (IBIDI), and 
allowed to harden for 30 minutes at 37° C. 12,000 HUVECs/well were seeded on the 
MatrigelTM and stimulated in triplicates overnight. The level of tube formation was determined 
by light microscopy and analyzed with the tube formation module of S.CORE analysis (S.CO 
LifeScience). 
 
 
11 Angiogenic Ex/In Vivo Assays 
11.1 Mice 
NMRI mice and male C57BL6 mice were purchased from Charles River Laboratories 
(Sulzfeld, Germany). 
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11.2 Mouse Aortic Ring Assay 
 
 
 
 
 
 
The abdominal arteries of NMRI mice were prepared, cut into rings and placed on the 
MatrigelTM. Aortic rings were incubated for two days in Endothelial Growth medium prior to 
stimulation with spongistatin 1. Endothelial cell sprouting was analyzed two days after all 
untreated rings sprouted. 
Additionally, CD31-staining was performed to ensure that sprouted cells are endothelial cells. 
Therefore, rings were washed one time with PBS and fixed in 1% formaldehyde for 25 
minutes at 37° C. Afterwards, rings were shaken overnight at 4° C in PBS, before they were 
incubated for at least 2 hours in blocking solution at 4° C. Then, rings were incubated for 6 
hours with the primary antibody against mouse CD31 (BD Biosciences, San Jose, CA, USA) 
1:200 in 1% BSA at 4°C. Next, rings were washed once with PBS before incubating them 
overnight with the secondary antibody, conjugated to AlexaFluor 488 (1:400 in 1% BSA, 
Invitrogen) at 4° C. Prior to microscopic observation (LSM 510 Meta), rings were washed at 
least 3 times with PBS, each for 1 hour at 4°C. 
 
11.3 Mouse Cornea Pocket Assay 
The mouse cornea pocket assay was performed in collaboration with Dr. Ivan Ischenko and 
PD Dr. Christiane J. Bruns from the Department of Surgery, Klinikum Großhadern at the 
Ludwig-Maximilians-University Munich. 
Corneal micropockets were created in C57BL6 mice with a modified von Graefe cataract 
knife. A micropellet (0.35×0.35 mm) of sucrose aluminium sulfate (Sigma-Aldrich, Steinheim, 
Germany) coated with Hydron polymer (Sigma-Aldrich, Steinheim, Germany) (10 µl of 12% 
Hydron in ethanol) containing approximately 80 ng of recombinant human FGF (R&D 
Systems, Wiesbaden, Germany) was implanted into each corneal pocket, as described (80). 
Control animals were implanted with pellets containing no growth factor only PBS. The pellet 
was positioned 1.2-1.4 mm from the corneal limbus. After implantation, erythromycin/ 
ophthalmic ointment was applied to each eye. Spongistatin 1 (in 2% DMSO, 0.9% NaCl) was 
administered intraperitoneally at a dose of 10 µg/kg daily for 5 days beginning from the first 
postoperative day (n = 5). The controls received vehicle only (n = 5). The maximal vessel 
length and clock hours of circumferential neovascularization were measured on the sixth day 
Blocking Solution  
BSA   1.0% 
Tween 20   0.1% 
Triton X-100 0.01% 
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after corneal implantation. The length of new vessels in the cornea was measured from the 
inside margin of vessels around the limbus to the tip of the longest neovascular sprout. The 
contiguous circumferential zone of neovascularization was measured as clock hours (length 
of the limbal vessel showing sprouts) with a 360° reticule (where 30° of arc equals 1 clock 
hour and 1 clock hour further corresponds to 1 mm limbal vessel length).  
 
 
12 The Orthotopic Pancreas Tumor Model 
The orthotopic tumor experiment was performed in collaboration with Dr. Ivan Ischenko and 
PD Dr. Christiane J. Bruns from the Department of Surgery, Klinikum Großhadern at the 
Ludwig-Maximilians-University Munich. 
 
12.1 Mice and Cell Line 
Female immunodeficient Balb/c nu/nu mice were purchased from Charles River Laboratories 
(Sulzfeld, Germany). Animal procedures were approved by the regional authorities. The 
human pancreatic cancer cell line L3.6pl was maintained in Dulbecco’s Minimal Essential 
Medium (Gibco, Invitrogen, Germany), supplemented with 10% fetal bovine serum (Biochrom 
AG, Berlin, Germany).  
 
12.2 Procedures 
L3.6pl human pancreatic cancer cells were injected orthotopically as described previously 
(81). Briefly, a small left abdominal flank incision was made and the spleen was exteriorized. 
Tumor cells (8 x 105 in 40 µL PBS) were injected into the subcapsular region of the pancreas 
just beneath the spleen. A 30-gauge needle, a 1 ml disposable syringe, and a calibrated 
pushbutton-controlled dispensing device were used to inject the tumor cell suspension. A 
successful subcapsular intrapancreatic injection of tumor cells was identified by the 
appearance of a fluid bleb without intraperitoneal leakage. To prevent such leakage, a cotton 
swab was held for 1 min over the site of injection. One layer of abdominal wound was closed 
by suture.  
Pancreatic tumors were allowed to become established for 6 days before initiation of 
treatment. Six days after implantation of tumor cells, mice were randomly assigned to one of 
the following groups of 10 mice each: 1) daily intraperitoneal administration of spongistatin 1 
at a dose of 10 μg/kg (in 2% DMSO, 0.9% NaCl); 2) daily intraperitoneal administration of 
vehicle solution for only (in 2% DMSO, 0.9% NaCl).  
IV MATERIALS AND METHODS 
 46 
12.3 Necroscopy 
The animals were sacrificed 21 days after the initiation of treatment, when > 50% of the 
control animals had become moribund. At the time of necropsy, all control and treated mice 
had developed primary pancreatic tumors. Primary pancreatic tumor size, liver and lymph 
node metastasis, and local peritoneal carcinosis were assessed. The tumor volume was then 
calculated using the formula V = π/6 × a × b × c, where a, b and c represent the length, 
width, and height of the mass. Tumor lesions were harvested, some were embedded in 
optimum cutting temperature (OCT) compound (Miles, Inc., Elkhart, IN, USA), snap-frozen in 
liquid nitrogen, and stored at -80° C, and some were stored in RNAlater at -80° C.  
 
Figure IV.4 The Pancreatic tumor model. 
(A) Schematic of the procedures of the orthotopic tumor experiment. SP1, spongistatin 1. (B) In 
necropsy, tumors were split and sections were either snap-frozen in liquid nitrogen (for EMSA 
and zymography) or stored in RNA later (for qRT-PCR and Western blot).  
 
 
13 Quantitative Real-Time PCR 
13.1 RNA-Isolation from Tissue Sections 
RNA was isolated from RNAlater-stored tumor lessions using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany). The tissues were homogenized, each about 25 mg in 600 µl RTL buffer 
(provided with the RNeasy Mini Kit) using the ultraturax homogenizer. Then procedures 
where followed as default by the RNeasy Mini Kit protocol. Finally, RNA was eluted with 
RNase-free water, amounts were quantified with the NanoDrop, and integrity of the RNA was 
controlled on an agarose-gel (18s and 28s rRNA subunits). 
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13.2 Reverse Transcription 
2 µg of total RNA were re-transcribed with random primers and the high capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) for 2 hours at 37°C. 
The cDNA was stored at -20° C until qRT-PCR. 
 
13.3 Quantitative Real-Time PCR 
Quantitative real-time PCR was performed on AB 7300 RealTime PCR system, using 
TaqMan Universal PCR Mastermix (Applied Biosystems). Probe and primers were from 
TaqMan gene expression assay (MMP-9: Hs00234579_m1; VEGF: Hs00900054_m1). PCR 
on GAPDH was used as reference, and serial dilution of cDNA served as standard curves. 
GAPDH primers were designed using the Primer Express® 2.0 software program (Applied 
Biosystems). GAPDH forward primer: 5'-GGG AAG GTG AAG GTC GGA GT-3'; reverse 
primer: 5'-TCC ACT TTA CCA GAG TTA AAA GCA G-3'; probe: 5'-ACC AGG CGC CCA 
ATA CGA CCA A-3'. Fluorescence-development was analyzed using the AB 7300 system 
software, and calculation of relative mRNA amount was done according to Pfaffel (82). 
 
 
14 Zymography 
 
5x Sample Buffer (store at -20° C) 
Tris/HCl 312.5 mM, pH 6.8 
Glycerol       50% 
SDS         5% 
Bromphenolblue    1.25% 
 
Developing Buffer 
Tris/HCl     50 mM, pH 6.8 
NaCl   200 mM 
CaCl2    5.0 mM 
Brij35   0.02% 
 
Protein samples for zymograms were prepared by homogenizing 40 mg of snap-frozen 
tissue in 400 µl RIPA-buffer without proteinase-inhibitors (IV 6.1 Total Cell Lysates), using 
the FastPrep homogenizator (2x 20 seconds, 4 m/s) and shredder columns, containing 
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Lysing Matrix D (MP Biomedicals, Illkirch, France). After centrifugation (14,000 rpm,            
15 minutes, 4°C), supernatants were collected and stored in 5x sample buffer at -80° C. 
Protein concentrations were determined by Bradford analysis and adjusted to equal 
amounts. 
Prior to loading on 10% SDS-Polyacrylamide gels containing 1% gelatin as substrate for 
MMPs, samples were not boiled, but incubated at room-temperature for 10 minutes. After 
running, the gel was incubated 30 minutes in 2.5% Triton X-100 to renature gelatinases. 
Subsequently, gels were equilibrated 30 minutes in developing buffer at room-temperature, 
before they were incubated in fresh developing buffer at 37° overnight. For quantification, 
gels were stained 45 minutes in Coomassie staining solution (IV 7.5 Staining Gels and 
Membranes), and afterwards destained with distilled water. Zymograms were scanned using 
the Odyssey Infrared Imaging System. Gelatin degradation was quantified with Odyssey 
scanning software 2.1. The linear range of the measurements was determined by preparing 
dilution series of the samples. Quantification of gelatinase activity has proven to be linear: 
m=1.0098. 
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Figure IV.5 Linearity of zymographic quantification of MMP-9 activity. 
A dilution series of a tissue sample was run on zymography and quantified by Licor Image Analysis. 
The linearity of MMP-9 measurements was proven since the slope of the calibration curve was 
m=1.0098. 
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15 Electrophoretic Mobility Shift Assay 
15.1 Extraction of Nuclear Proteins 
 
Extraction Buffer A  Extraction Buffer B 
HEPES, pH 7.9 10 mM  HEPES, pH 7.9 20 mM 
KCl 10 mM  NaCl 0.4 mM 
EDTA 0.1 mM  EDTA 0.1 mM 
EGTA 0.1 mM  EGTA 0.1 mM 
DTT 1.0 mM  DTT 1.0 mM 
PMSF 0.5 mM  PMSF 0.5 mM 
   Glycerol 25% 
 
For nuclear preparation, 40 mg of snap-frozen tissue was homogenized in 400 µl nuclear 
extraction buffer A using FastPrep homogenization system. Tissues and buffer A were filled 
into tubes containing Lysing Matrix D and homogenized 20 seconds with 4m/s speed in 
FastPrep. After centrifugation (1,500 rpm, 5 minutes, 4° C) supernatants were discarded and 
sediments were incubated in fresh buffer A containing 0.625% Nonidet NP-40 for 15 minutes. 
Probes were centrifuged (14,000 rpm, 1 minute, 4° C), supernatants removed, and pellets 
incubated for 30 minutes under shaking at 4° C in 40 µl nuclear extraction buffer B. After 
centrifugation (14,000 rpm, 5 minutes, 4° C), supernatants were collected and frozen at         
-80° C. Protein concentrations were determined by Bradford assay (IV 6.1 Protein 
Quantification). 
 
15.2 Electrophoretic Mobility Shift Assay 
 
5x Binding Buffer  Loading Buffer 
Tris/HCl   50 mM  Tris/HCl 250 mM 
NaCl 250 mM  Glycerol    40% 
MgCl2  5.0 mM  Bromphenolblue   0.2% 
EDTA  2.5 mM    
Glycerol   20%    
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Transcription factor-specific oligonucleotides were 5’ end-labeled with [γ32P]-ATP using the 
T4 polynucleotide kinase. Oligonucleotides for HIF-1α with the consensus sequence 5’-TCT 
GTA CGT GAC CAC ACT CAC CTC-3’ were purchased from Santa Cruz Biotechnology, Inc.  
20 µg protein were incubated with 2 μg poly(dIdC) and 3 μl of freshly prepared reaction buffer 
for 10 minutes at room temperature. The reaction buffer consisted of 450 µl of 5x binding 
buffer, 50 µl Gel loading buffer, and 1 mM DTT. The binding-reaction was started by adding 1 
µl of the radioactive oligonucleotide and carried out for 30 minutes at room-temperature. The 
protein-oligonucleotide complexes were separated by gel electrophoresis (Mini-Protean III, 
BioRad) with 0.25 x TBE buffer at 100 V for 60 minutes using non-denaturating 
polyacrylamide gels (5% PAA, 20% glycerol). After electrophoresis, gels were exposed to 
Cyclone Storage Phosphor Screens (Canberra-Packard, Schwadorf, Austria) for 24 hours, 
followed by analysis with a phosphor imager station (Cyclone Storage Phosphor System, 
Canberra-Packard). 
 
 
16 Statistical Analysis 
Statistic analyses were performed with SigmaStat version 3.5 statistic software (Systat 
Software Inc., Richmond, CA). Data were expressed as mean value ± S.E.M., and analyzed 
using One Way ANOVA, Student’s t-test, or Rank On Sum-test. P<0.05 was considered as 
statistical significant *, p<0.05; **,  p<0.01; ***,  p<0.001. 
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A Spongistatin 1 Exerts Strong Impact on Pancreatic Tumor 
Progression and Metastasis In Vivo 
 
1 Orthotopic Tumor Model 
The orthotopic tumor experiment was performed in collaboration with Dr. Ivan Ischenko and 
PD Dr. Christiane J. Bruns from the Department of Surgery, Klinikum Großhadern at the 
Ludwig-Maximilians-University Munich. 
 
1.1 Spongistatin 1 Inhibits Pancreatic Tumor Progression 
In the orthotopic nude mouse model, the efficacy of spongistatin 1 on L3.6pl pancreatic 
tumor in vivo was demonstrated. Six days after tumor implantation, mice were treated daily 
with spongistatin 1 or solvent i.p. for 22 days. During this time, tumor size was calculated by 
palpation through the skin. 15 days after tumor implantation, tumor growth strongly increased 
in the control animals. This tumor progression was significantly reduced by treatment with 
spongistatin 1 (Figure V.1).  
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Figure V.1 Spongistatin 1 inhibits pancreatic tumor progression. 
L3.6pl human pancreatic cancer cells were injected into the pancreas of nude mice. Six days 
after implantation of tumor cells, mice were either treated (i.p., daily) with spongistatin 1    (10 
μg/kg; n=10) or vehicle (2% DMSO, in NaCl, control; n=10). Progression of tumor volume was 
estimated by palpation through the skin. The diagram shows time course of tumor growth in 
vehicle (control) and spongistatin 1-treated animals. Data are shown as mean ± S.E.M., 
*p<0.05, student’s t-test. 
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1.2 Necropsy Reveals Strong Efficacy of Spongistatin 1 on Pancreatic Tumor 
At the day of necropsy, mice were finally weight, and tumor volume and weight were 
assessed. Treatment with spongistatin 1 significantly reduced tumor volume, as well as 
tumor weight compared to animals that have received vehicle treatment only (Figure V.2). 
Moreover, spongistatin 1 did not cause a reduction of body weight (vehicle treated group 
18.6 g ± 2.46; spongistatin 1 treated group 19.0 g ± 2.18 at time of necropsy). 
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Figure V.2 Necropsy data. 
(A) Tumor volume and tumor weight were quantified at time of necropsy (day 22 after initiation 
of the therapy), as described in ‘Material and Methods’. Treatment with   spongistatin 1 i.p. 
strongly reduced both tumor volume and tumor weight. Bars, the mean ± S.E.M. of all 
pancreases, ***p<0.001, *p<0.05, student’s t-test. (B) Representative photos of pancreatic 
tumors at time of necropsy (day 22 after initiation of the therapy).  
 
1.3 Metastasis is Significantly Reduced by Spongistatin 1 
The primary tumors were removed, and the liver and the surrounding tissue were visually 
scanned for metastases and peritoneal carcinosis (nodules ≥1 mm in diameter). 
Spongistatin 1-treatment significantly reduced the incidence of metastases: all control 
animals, but only three of the spongistatin 1-treated mice had incidences of metastases in 
lymph nodes. Likewise, two of nine spongistatin 1-treated mice developed liver metastases 
compared to nine of ten mice in the control group. Additionally, peritoneal carcinosis was 
reduced to half, when mice were treated with spongistatin 1 (Table V.1). 
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Table V.1 Treatment with spongistatin 1 decreased the incidences of metastases. 
In necropsy, regional lymph nodes and liver were visually examined for metastases (visible 
nodules ≥1 mm in diameter). In addition, incidence of peritoneal carcinosis was determined. 
Incidences are presented as number of animals with metastases per total number of animals. 
 
Metastases  
Treatment Lymph nodes Liver Peritonial carcinosis 
control 10/10 9/10 9/10 
10 µg/kg/day spongistatin 1 3/9 2/9 5/9 
 
 
2 The Influence of Spongistatin 1 on Hypoxia Inducible Factor 1α 
2.1 Stabilization of HIF-1α Is Strongly Reduced by Spongistatin 1 In Vitro 
Hypoxia-induced signaling via stabilization of the transcription factor HIF-1α is strongly 
associated with tumor growth and the formation of metastases. Further, the inhibition of HIF-
1α was shown to reduce tumor progression (83). Since it was previously demonstrated that 
tubulin-binding drugs inhibit HIF-1α signaling in vitro, the impact of spongistatin 1 on HIF-1α 
stability was investigated in pancreatic L3.6pl cells.  
Stimulation with CoCl2 mimics hypoxia, by stabilizing the transcription factor HIF-1α (84). In 
Western blot analysis, incubation of L3.6pl cells with 100 nM CoCl2 resulted in increased 
amounts of HIF-1α in comparison to control cells. Co-stimulation with 1.0 nM spongistatin 1 
inhibited clearly CoCl2-induced stabilization of HIF-1α (Figure V.3 A). 
 
2.2 Spongistatin 1 Has No Influence on HIF-1α Activity In Vivo 
Due to the importance of hypoxia-mediated signaling in tumor progression, pancreatic tumor 
sections were investigated for effects of spongistatin 1 on HIF-1α activity in vivo. From all 
tissue samples, nuclei were isolated in order to investigate the DNA-binding activity of HIF-
1α to its consensus sequence by EMSA. Quantification of EMSA-studies revealed no 
significant difference in HIF-1α-binding activity between the control group and the 
spongistatin 1 group (Figure V.3 B). Further, the mRNA levels of VEGF were quantified as 
indicator for HIF-1α activity, since VEGF is the most important angiogenic factor regulated by 
HIF-1α. However, there were no significant differences in both treatment-groups on VEGF 
mRNA levels (Figure V.3 C).  
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Figure V.3 Spongistatin inhibits HIF-1α activity in vitro, but not in vivo. 
(A) Stimulation of pancreatic L3.6pl cells with 100 nM CoCl2 for 4 hours resulted in stabilization 
of HIF-1α. Co-stimulation of spongistatin 1 (1.0 nM) reduced CoCl2-induced stabilization of HIF-
1α. Ponceau S-staining proved equal protein loading. (B) EMSA of tumor tissue sections 
revealed that spongistatin 1 had no significant impact on the DNA-binding activity of HIF-1α (left 
panel). Analysis of HIF-1α transcription product VEGF mRNA in tumor tissue sections (right 
panel) has shown no influence of spongistatin 1 on HIF-1α activity in vivo. Bars, the mean ± 
S.E.M. of all pancreases, p>0.05, n.s., not significant, student’s t-test. 
 
 
3 Matrix Metalloproteinase 9 Is Reduced by Spongistatin 1 In Vivo 
3.1 Reduction of MMP-9 mRNA and Protein Levels by Spongistatin 1 
In many tumors, including pancreatic cancer, the overexpression of MMPs is correlated with 
metastasis. Quantitative real-time PCR-analysis of tissue samples from the pancreatic in vivo 
experiment revealed that the amount of MMP-9 mRNA was significantly reduced in animals 
treated with spongistatin 1, which is well in line with the reduced incidences of metastases 
(Figure V.4 A).  
A reduction of MMP-9 mRNA-level is supposed to result in reduced protein-levels of MMP-9. 
Thus, MMP-9 protein was quantified by Western blot analysis and normalized to β-actin 
(Figure V.4B). Level of MMP-9 protein were clearly reduced (31.52% vs. control animals), in 
the tissues of spongistatin 1-treated mice. The expression of MMP-2 was very low, and even 
balancing up-regulation of MMP-2 in spongistatin 1-animals could not be detected.  
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Figure V.4 Spongistatin 1 reduces MMP-9 mRNA and protein level. 
(A) Quantitative real-time PCR analysis of tumor tissues showed significant reduced MMP-9 
mRNA level in tissues of spongistatin 1-treated animals as compared to vehicle-treated (control) 
animals. (B) Quantification of MMP-9 protein level via Western blot analysis of all animals 
confirmed reduced amounts of MMP-9 in spongistatin 1-treated mice. MMP-9-protein was 
normalized to β-actin, and MMP-9 expression in control animals was set as 1.0. The blot shows 
a representative experiment based on n=3 tissue samples, respectively. Bars, the mean ± 
S.E.M. of all pancreases, *p<0.05, **p<0.01, student’s t-test. 
 
3.2 Zymography Reveals Reduced MMP-9 Activity in Spongistatin 1-Treated Mice 
The clinically relevant factor of MMP-9 quantification in tumor tissues is not the level of  
MMP-9 mRNA or protein, but the amount of enzymatic active MMP-9. Thus, gelatinase-
activity of MMP-9 in the tumor sections was determined by zymography. MMPs exert their 
enzymatic activity in extracellular space, degrading gelatin and collagen elements of the 
extracellular matrix, and are therefore quite stable in their activity. In zymography, MMPs can 
be separated under non-denaturating conditions in a modified SDS-PAGE. After refolding, 
the MMPs degrade the gelatin cast in the separation gel. Coomassie-staining of the gels 
reveals the sites of gelatinase-activity by means of unstained areas. 
Comparing an MMP-marker (kindly donated by Dr. Christian Ries) with a tissue sample 
identified MMP-9 to be the most prominent MMP in the pancreatic tumor, whereas detection 
of MMP-2 was marginal (Figure V.5 A). Molecular weights of MMPs can vary, since they are 
cell type- and stimulus-specific posttranslational modified (85). Zymography of tumor tissue 
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showed a reduction of MMP-9 gelatinase-activity to 71.1% in the tumors of spongistatin 1-
treated mice as compared to untreated mice (Figure V.5 B).   
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Figure V.5 MMP-9 gelatinase activity is reduced in spongistatin 1-treated mice. 
(A) Zymogram of a tissue sample (tissue) and a well-characterized MMP-marker. 
Posttranslational modifications results in a higher molecular weight of the MMP-9 band in the 
tissue sample compared to pro-MMP-9 in the marker. Also small amounts of proMMP-2 and 
MMP-2 could be detected in the tissue sample. (B) The zymogram shows one representative 
analysis of tumor tissue sections (n=3) of both control and spongistatin 1-treated mice. Bars 
(mean ± S.E.M.) represent the densitometric analysis of MMP-9 activity of all control (n=10) or 
spongistatin1-treated tumor tissues (n=9). MMP-9 activity of tissue samples of untreated mice 
was set as 1. Bars, the mean ± S.E.M. of tissue sections of all animals. *p<0.05, student’s t-test. 
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B Effects of Spongistatin 1 on Angiogenesis In Vitro and In Vivo 
 
4 Disassembly of Microtubules 
4.1 Spongistatin 1 Disassembles Microtubules in Endothelial Cells 
 
0 h
4 h
12 h
β-tubulin
0.1       1         2
spongistatin 1 [nM]
paclit.control
β-tubulin
β-actin
β-actin
insoluble 
fraction
soluble 
fraction
A B
 
Figure V.6 Spongistatin 1 causes time and does-dependent disassembly of microtubules. 
(A) Live cell imaging: GFP-tubulin transfected HUVECs were stimulated with 2.0 nM 
spongistatin 1 for 16 hours. The clear structures of microtubules at the beginning of the record 
(0h) slowly dispersed with prolonged spongistatin 1-incubation (4h and 12h). (B) Cell lysates of 
paclitaxel (paclit.) and spongistatin 1-stimulated HUVECs were separated in PIPES buffer-
soluble and -insoluble fractions. Using an antibody against β-tubulin, tubulin heterodimers were 
detected in the soluble fraction and polymerized microtubules in the insoluble fraction. 
Incubation with spongistatin 1 reduced polymerized microtubules dose-dependently as judged 
by the decreasing amounts of β-tubulin in the PIPES-insoluble fraction, whereas paclitaxel       
(1 µM) increased microtubules polymerization. The equality of protein loading was controlled by 
detection of β-actin. 
 
To verify microtubule-depolymerizing properties of spongistatin 1 in endothelial cells, two 
different approaches were pursued to characterize the impact of spongistatin 1 on the tubulin 
cytoskeleton of HUVECs. First, live cell imaging of GFP-tubulin transfected HUVECs, 
incubated with 2.0 nM spongistatin 1, was performed. Time-lapse microscopy of these cells 
documented the disassembly of the microtubules by spongistatin 1 over 16 hours. The GFP-
signal showed clearly structured microtubules in the beginning of the record. With increased 
period of spongistatin 1-stimulation, microtubules collapsed and only diffuse GFP-signals all 
over the cell were detectable (Figure V.6 A).  
Since the expression of recombinant proteins like GFP-tubulin is likely to evoke artifacts, the 
disassembly of the microtubules by spongistatin 1 was also investigated in non-transfected 
HUVECs. Therefore, endothelial cells were incubated for 4 hours with different 
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concentrations of spongistatin 1 (0.1 nM, 1.0 nM, and 2.0 nM) and paclitaxel (1.0 µM, serving 
as crosscheck), respectively. After incubation, cells were fractionated in two fractions: one 
containing soluble tubulin heterodimers (PIPES-soluble fraction), and one containing 
polymerized microtubules (PIPES-insoluble fraction). Paclitaxel, which is a microtubule-
stabilizing drug, caused an increase of tubulin in the fraction of polymerized microtubules, as 
expected. In contrast, incubation with spongistatin 1 induced a dose-dependent decrease of 
tubulin in this fraction as a result of microtubules disassembly (Figure V.6 B). 
 
4.2 Spongistatin 1 Influences the Morphology, the Arrangement of Mitochondria, 
and Membrane Trafficking of Endothelial Cells 
The inhibition of microtubules - a central element of the cytoskeleton - by spongistatin 1 is 
supposed to entail structural and functional changes in the endothelial cell. Under control 
conditions, endothelial cells are spindle shaped. After incubating a confluent HUVEC-
monolayer with spongistatin 1 (1.0 nM, 8 hours), endothelial cells rounded up and added the 
appearance of a cobblestone pavement to the monolayer (see Figure V.7 A). 
Microtubules are essential for the intracellular arrangement of organelles. Mitochondria 
arrangement in spongistatin 1-stimulated cells was investigated by live cell imaging. In the 
beginning of the record, mitochondria were distributed over the whole cell. Prolonged 
incubation with spongistatin 1 (1.0 nM, 3 hours) induced translocation of the mitochondria 
near the nucleus (Figure V.7 B).  
Besides the arrangement of mitochondria, also membrane trafficking and vesicle transport 
are microtubule-dependent. To investigate the influence of spongistatin 1 on the membrane 
flow of endothelial cells, HUVECs were incubated with a membrane-integrating dye. Under 
control conditions, HUVECs took up the dye within 15 minutes, and the dye could be 
detected in vesicular compartments in the cell. In spongistatin 1 pre-incubated HUVECs   
(1.0 nM, 3 hours) the membrane-dye remained distributed over the cytoplasmic membranes. 
Thus, cells were no longer able to incorporate the dye, indicating that the membrane 
trafficking was discontinued upon spongistatin 1-treatment (Figure V.7 C).  
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Figure V.7 Spongistatin 1 influences the morphology of HUVECs. 
(A) In a confluent monolayer, HUVECs were spindle-shaped under control conditions. After 
spongistatin 1-treatment (1.0 nM, 8 hours), cells round up and the monolayer became a 
cobblestone structure. (B) In the beginning of spongistatin 1-treatement of HUVECs (1.0 nM, 0 
hours), mitochondria were distributed in the whole cytoplasm, whereas prolonged stimulation 
(1.0 nM, 3 hours) caused a perinuclear localization of mitochondria. (C) Membrane trafficking in 
non-stimulated HUVECs was determined by accumulation of an externally applied membrane 
dye in intracellular vesicles. Spongistatin 1 (1.0 nM, 3 hours) reduced membrane trafficking, 
since most of the membrane dye remained on the cell surface. 
 
 
5 Cytotoxicity, Cell Cycle, and Apoptosis 
5.1 Cytotoxicity of Spongistatin 1 in Endothelial Cells 
The cytotoxicity of spongistatin 1 was measured in a cell viability assay. Functional intact 
cells are able to reduce metabolically the chromophore resazurin to resorufin. Resorufin 
emits fluorescence at 590 nm, and thus can be quantified fluorometrically. Confluent and 
proliferating HUVECs were stimulated with increasing concentrations of spongistatin 1 for   
24 hours. Resazurin was added to the medium and after 4 hours of incubation the 
conversion of resazurin to resorufin was determined. Proliferating cells showed a significant 
reduction of metabolic activity at a concentration as low as 5.0 nM   spongistatin 1, indicating 
an acute cytotoxicity of spongistatin 1. In confluent HUVEC, metabolic activity was 
significantly reduced starting from 50.0 nM spongistatin 1. Thus, confluent HUVECs can 
tolerate a 10-fold higher concentration of spongistatin 1 than proliferating cells (Figure V.8).  
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Figure V.8 Determination of the cytotoxicity of spongistatin 1. 
The conversion of resazurin to resorufin is an indicator of the metabolic activity and therefore 
the viability of cells. HUVECs showed a dose-dependent inhibition of metabolic activity upon 
spongistatin 1-treatment. Apparently, proliferating HUVECs are more sensitive towards 
cytotoxic effects of spongistatin 1 than confluent cells. Data are expressed as the mean             
± S.E.M., *p<0.05, One Way ANOVA. 
 
5.2 Spongistatin 1 Induces Cell Cycle Arrest and Apoptosis 
Tubulin antagonists disrupt the mitotic spindle of dividing cells, and thereby cause cell cycle 
arrest in the G2 to M phase transition, which sooner or later results in apoptosis                   
(III 4.3.1 The Mitotic Spindle). By staining the chromatin of endothelial cells with the 
intercalating agent propidium iodide, cell cycle phases and DNA-fragmentation can be 
determined in flow cytometry, since the fluorescence of propidium iodide depends on DNA-
condensation, DNA-fragmentation, and the state of chromosome replication. Thus, in flow 
cytometric measurements, each cell cycle phase generates a characteristic peak which can 
be quantified. (Figure V.9 A).  
Incubation with spongistatin 1 caused a G2 to M-phase arrest in HUVECs, as expected. 
Starting from a concentration of 1.0 nM spongistatin 1, significantly more cells were in G2/M 
phase (Figure V.9 B, left panel). The sub-G1 peak presents apoptotic cells. Quantification of 
this peak revealed a significant increase of apoptotic cells at a concentration as low as       
2.0 nM spongistatin 1 (Figure V.9 B, right panel). Compared to the established tubulin-
binding drugs vinblastine, paclitaxel, or CA4P, which caused G2/M-phase arrest and 
apoptosis, too, effects of spongistatin 1 occurred at concentrations well below (Figure V.9 C).  
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Figure V.9 Flow Cytometric Cell Cycle Measurements. 
(A) FACS data files of different spongistatin 1-treatment groups. Cell cycle phases are 
determined and quantified by characteristic fluorescence peaks of the DNA intercalating 
compound propidium iodide. (B) Spongistatin 1-stimulated HUVECs revealed a dose-dependent 
G2/M phase arrest starting from 1.0 nM spongistatin 1. Apoptosis was significantly increased at 
a concentration of 2.0 nM spongistatin 1. (C) Comparison of spongistatin 1 with the established 
tubulin antagonists vinblastine, CA4P, and paclitaxel revealed spongistatin 1 to induce G2/M 
arrest and apoptosis most effectively. Data are expressed as the mean ± S.E.M., *p<0.05, One 
Way ANOVA. 
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6 Effects of Spongistatin 1 on Endothelial Proliferation 
6.1 Spongistatin 1 Strongly Inhibits Endothelial Proliferation In Vitro 
In the angiogenic in vitro proliferation assay, endothelial cells were seeded in low density at 
day -1, stimulated with the respective compound at day 0, and proliferation was evaluated at 
day 3 (72 hours) by staining the cells with crystal-violet (Figure V.10 A). The staining intensity 
of crystal-violet is proportional to cell proliferation. Relative proliferation was related to the 
number of cells at day 0. Proliferation of control cells without stimulus was set as 100% 
proliferation. 
Astonishingly, proliferation of HUVECs was already strongly inhibited at the very low 
concentration of 100 pM spongistatin 1, whereas more than 25 to 500-time higher 
concentrations of vinblastine (2.5 nM), CA4P (7.5 nM), or paclitaxel (50.0 nM) were needed 
to inhibit endothelial proliferation (Figure V.10 B).  
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Figure V.10 In Vitro Proliferation Assay. 
(A) In the proliferation assay, HUVECs were stimulated for 3 days (72 hours) with increasing 
concentrations of spongistatin 1, vinblastine, CA4P, and paclitaxel. (B) Spongistatin 1 strongly 
inhibited proliferation at a concentration of 100 pM, whereas 25-500-time higher concentrations 
of the other investigated tubulin antagonists were needed. Data are expressed as the mean      
± S.E.M., *p<0.05, One Way ANOVA. 
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6.2 Proliferative Signaling: Spongistatin 1 Inhibits AKT-Phosphorylation 
The effects of spongistatin 1 on important signaling pathways, which are involved in 
endothelial proliferation, were investigated by Western blot analysis. The kinases ERK1/2 
and AKT have been shown to be of particular importance in angiogenesis and endothelial 
proliferation (III 6.1 Initiation of Angiogenesis: Endothelial Proliferation). The activity of both 
kinases can be judged by the phosphorylation state of distinct residues. The activity of 
ERK1/2 depends on the phosphorylation at the critical residues in the activation loop 
T202/Y204 and T185/Y187, respectively (86). The phosphorylation of both residues T308 in 
the activation loop and S463 in the C-Terminus is essential for AKT activity (87). 
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p-Akt T308
Akt tot
10% FCS +SP10% FCS10% FCS    0% FCS    +SP1
ERK1/2 tot
p-ERK1/2
B C
0h 4h 5h,15’
starvation
pre-incubation
SP1 harvest
A
5h
stimulus
10% FCS
10% FCS 10% FCS 
 
 
Figure V.11 Spongistatin 1 inhibits the phosphorylation of AKT. 
(A) Stimulation scheme: HUVECs were starved for 5 hours. 1 hour prior to FCS stimulus, cells 
were pre-incubated with spongistatin 1 (SP1, 2.0 nM). After 15 minutes of FCS-stimulation, cells 
were harvested and the phosphorylation state of ERK1/2 and AKT was determined by Western 
blot analysis. Cells without FCS-stimulus (0% FCS) served as negative control. (B) Starving 
endothelial cells (0% FCS) reduced phosphorylation of ERK1/2. Addition of FCS (10% FCS) 
restored phosphorylation. The pre-incubation with spongistatin 1 (2.0 nM, 1 hour) had no 
influence on phosphorylation of ERk1/2. (C) Stimulation with 10% FCS after a period of 
starvation strongly induced the phosphorylation of AKT on T308 and S473. Pre-incubation of 
spongistatin1 inhibited FCS-induced phosphorylation of AKT at both sites. 
 
To induce the phosphorylation of both ERK1/2 and AKT, HUVECs were starved for 5 hours 
before stimulation with FCS (Figure V.11 A). Deprivation of growth factors decreased 
phosphorylation of ERK1/2 at the residues T202/Y204 and T185/Y187 (0% FCS). 
Phosphorylation could be restored by addition of FCS (10% final concentration). The addition 
of spongistatin 1 (2.0 nM, 1 hour) prior to FCS-stimulus did not reduce the phosphorylation of 
ERK 1/2 (Figure V.11 B).  
In accordance to ERK1/2, starvation of HUVECs (0% FCS) abolished phosphorylation of 
AKT at both critical residues, which was recovered by addition of FCS (10% FCS). In 
contrast to ERK1/2 phosphorylation, pre-incubation with 2.0 nM spongistatin 1 strongly 
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reduced the FCS-induced phosphorylation of AKT at T308 and S473. Thus, activation of AKT 
seems to be inhibited by spongistatin 1-treatment. 
 
 
7 The Impact of Spongistatin 1 on Endothelial Migration  
7.1 Migration of HUVECs Is Inhibited by Spongistatin 1 
The influence of spongistatin 1 on endothelial cell migration was investigated in a scratch 
assay. Due to their function as vascular barrier, endothelial cells have the natural impulse to 
close gaps in the united cell structure. Thus, wounding an endothelial monolayer with a 
pipette-tip stimulates the cells to migrate into cell-free area and to close the wound.  
Endothelial cells in culture medium closed the inflicted scratch overnight (positive control, 
100% migration), whereas wound closure was completely abolished, when cells were 
incubated in starvation medium (negative control, 0% migration). The addition of  
spongistatin 1 to the culture medium effectively inhibited wound closure in a dose-dependent 
manner with an IC50 of approximately 1.0 nM, and was therewith again more potent than the 
established tubulin-antagonists vinblastine (7.5 nM), C4AP (10.0 nM), or paclitaxel (25.0 nM) 
(Figure V.12 A). The degree of wound closure was quantified by using a migration software 
tool, which detects and quantifies the cell-free area (Figure V.12 B). 
 
7.2 Spongistatin 1 Deregulates the Arrangement of F-Actin in HUVECs 
The actin cytoskeleton is essential in generating cellular protrusions. Hence, alterations in   
F-actin organization could be expected in cells that are inhibited in migration. F-actin in 
growth factor deprived cells (starvation medium) was organized in cortical rings and 
lamellipodia only barley existed (Figure V.12 C, left panel). In contrast, F-actin in migrating 
HUVECs (culture medium) was arranged in fibers in the cell body and lamellipodia at the 
leading edge. Both were directed towards the wound (Figure V.12 C, middle panel). 
Spongistatin 1-treated cells exhibited the characteristics of F-actin arrangement in both 
migrating and non-migrating cells. Actin fibers in the cell body and cortical rings were formed. 
Furthermore, the appearance of lamellipodia was reduced upon spongistatin 1-treatment 
(Figure V.12 C, right panel).  
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Figure V.12 Spongistatin 1 inhibits migration of HUVECs. 
(A) Spongistatin 1, vinblastine, CA4P, and paclitaxel inhibited wound closure of a scratched 
HUVEC monolayer in a dose-dependent manner. Data are expressed as the mean ± S.E.M., 
*p<0.05, One Way ANOVA. (B) Representative images of the quantification of wound healing 
(S.CORE image analysis). Endothelial cells are colored in yellow; the cell-free area is marked in 
grey. (C) Actin-cytoskeleton (red) in migrating HUVECs: under spongistatin 1-treament, the 
formation of lammelipodia is reduced, and the formation of cortical rings is increased, compared 
to control cells in culture medium without spongistatin 1. 
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7.3 The Chemotaxis of Endothelial Cells is Inhibited by Spongistatin 1 
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Figure V.13 Spongistatin 1 reduces dirtectional migration in HUVECs.  
(A) Track plots of control cells and spongistatin 1-treated cells of representative chemotaxis 
experiments are shown. The starting point of each single cell is placed in the center of the 
diagram. Tracks of cells, moving towards FCS are displayed in black, the tracks of cells without 
attraction to FCS in red. The blue point symbolizes the y-center of mass. (B) Analysis of y-
forward (y-forward migration index of each cell), y-center of mass (y-value center of mass of all 
tracking endpoints), Euclidean distance (direct distance between starting point and endpoint), 
accumulated distance, and velocity (pixel/slide), means of control cells were set as 1.0. 
Accumulative distance and velocity were not significantly affected by spongistatin 1, indicating 
that not migration itself, but directionality was inhibited. Bars, the mean ± S.E.M, *p<0.05, n.s., 
not significant, student’s t-test. 
 
The influence of spongistatin 1 on directed migration of endothelial cells was investigated in 
a chemotaxis assay. In this assay, HUVECs were exposed to a serum-gradient ranging from 
0% FCS to 10% FCS. Untreated HUVECs were attracted by FCS and moved along a serum-
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gradient. Their directionality to the serum was expressed in y-values, since the gradient was 
set up along the y-axis of the chemotaxis-chamber (Figure IV.3 and Figure V.13 A). The 
values of control HUVECs were set as 1.0. Thus, the migration index of each single cell in 
FCS gradient referred as ‘y-forward‘ was 1.00±0.264 and center of mass of all tracking 
endpoints in FCS gradient referred as ‘y-center of mass’ was 1.00±0.078 in untreated 
HUVECs. In contrast, spongistatin 1-treated cells were reduced in their directionality for the 
FCS gradient, which is reflected in their values for y-forward (-0.049±0.087) and y-center of 
mass (-7.344*10-3±0.117). 
Besides the directionality for the FCS-gradient, single parameters of chemotactic migration 
were evaluated. The Euclidean distance is the direct distance between starting point and 
endpoint of a cell-track and was reduced to half (0.548±0.024) by treatment with 1.0 nM 
spongistatin 1. This finding is well corresponding to spongistatin 1 IC50-values in the wound-
healing assay (Figure V.12 A). Astonishingly, accumulative distance and velocity were not 
reduced upon treatment with spongistatin 1, indicating that spongistatin 1 does not disrupt 
cellular movement itself (chemokinesis), but the ability of HUVECs for directional migration 
(Figure V.13 B). 
 
7.4 Spongistatin 1 Seems to Have No Influence on MTOC-Orientation  
A 2 h 6 h 10 h 13 h
B control spongistatin 1
 
Figure V.14 Spongistatin 1 has no influence on MTOC-orientation. 
(A) Life cell imaging of GFP-Tubulin transfected cells incubated with 2.0 nM spongistatin 1. The 
MTOC is visible as bright point near the nucleus (white arrows), even after the disassembly of 
interphase microtubules. The yellow arrows indicate the direction of HUVEC migration, which is 
also traceable by the localization of the upper and the lower cell. (B) Cdc42 staining (red) in 
GFP-tubulin transfected cells. The merge of both signals (yellow) shows the co-localization of 
Cdc42 and the MTOC in control and spongistatin 1-treated cells (5.0 nM, 30 minutes). 
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The re-orientation of the MTOC is essential for directed migration, and is regulated by the 
small RhoGTPase Cdc42. Time-lapse microscopy of GFP-tubulin transfected cells show the 
disassembly of microtubules. Furthermore, GFP-tubulin expression in the cell allows tracking 
the orientation of the MTOC, which is visible as bright structure in close neighborhood to the 
nucleus. Treatment with spongistatin 1 did neither disassemble the MTOC structure nor had 
it any influence on its orientation (Figure V.14 A). Cdc42, the master regulator of MTOC re-
orientation, seemed to be associated with the centrosome structure, also under spongistatin 
1 treatment (Figure V.14 B). 
 
 
8 Tube Formation Is Inhibited by Spongistatin 1 
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Figure V.15 Spongistatin 1 Inhibits Endothelial Tube Formation. 
(A) Representative images of the tube formation assay. Quantification was done by S.CORE 
image analysis. Tubes are marked in dark grey, nodes in light grey. (B) The formation of 
endothelial tubes on MatrigelTM was reduced to half by 1.0 nM spongistatin 1. Bars, the mean    
± S.E.M, *p<0.05, One Way ANOVA. 
 
The inhibition of endothelial tube formation on MatrigelTM is a characteristic attribute of 
antiangiogenic agents. In time-lapse microscopy, freshly seeded HUVECs formed a tubular 
network on MatrigelTM within only 4-7 hours. However, upon addition of 1.0 nM spongistatin 1 
to the seeding medium, cells seemed to be no longer able to adhere properly to MatrigelTM, 
and therefore were not able to form tubes (data not shown). Quantification of tube formation 
by S.CORE tube formation software showed about 50% reduction in tube length and number 
of nodes by 1.0 nM spongistatin 1 (Figure V.15).  
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9 Effects of Spongistatin 1 in Angiogenic Ex/In Vivo Assays 
9.1 Spongistatin 1 Inhibits Endothelial Sprouting 
In the ex vivo mouse aortic ring model, slices of mouse aortas were incubated on MatrigelTM 
for several days. Without spongistatin 1 (control), endothelial cells sprouted out of the aortic 
ring and spanned the MatrigelTM within 3-5 days. Stimulation of the aortic rings with 0.5 nM 
spongistatin 1 yielded reduced sprout formation, which was completely suppressed by 
treatment with 1.0 nM spongistatin 1 (Figure V.16 A).  
CD31 is an endothelium-specific surface antigen. Staining the aorta slices and the sprouted 
cells with CD31-specific antibody verified that in fact endothelial cells have sprouted and not 
for instance smooth muscle cells (Figure V.16 B). 
 
control
1.0 nM spongistatin 1
0.5 nM spongistatin 1
B CD31-stainingA Endothelial sprouting
sprouted 
cells
inner 
layer
vessel 
wall
vessel 
lumen
 
Figure V.16 Endothelial sprouting is inhibited by spongistatin 1. 
(A) Representative pictures of the aortic ring assay show vessels of the three different treatment 
groups control, 0.5, and 1.0 nM spongistatin 1. In control, endothelial cells have spread out of 
the aorta solices, and cover the MatrigelTM. The sprouting was dose-dependently inhibited by 
spongistatin 1. (B) CD31-staining proved that sprouted cells were endothelial cells. 
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9.2 Neovascularization In Vivo Is Reduced by Spongistatin 1 
Antiangiogenic properties of spongistatin 1 in vivo were determined in the mouse corneal 
micropocket assay. This experiment was performed in collaboration with Dr. Ivan Ischenko 
and PD Dr. Christiane J. Bruns from the Department of Surgery, Klinikum Großhadern at the 
Ludwig-Maximilians-University Munich. Spongistatin 1 was administered intraperitoneally to 
investigate its impact on neovascularization after 6 days of stimulation with FGF. 
Pellets containing sucrose aluminium sulfate alone without growth factors did not induce 
corneal neovascularization (data not shown). Corneal neovascularization induced by FGF in 
spongistatin 1-treated animals was markedly reduced compared to vehicle-treated control 
animals. Quantitative comparison showed that all parameters relevant for measuring the 
extent of corneal neovascularization were significantly lower in spongistatin 1-treated 
animals: the circumference of neovascularization and the vessel length in the corneas from 
spongistatin 1-treated mice were reduced by 37% and 53% respectively, compared to 
controls (Figure V.17). 
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Figure V.17 Spongistatin 1 inhibits the neovascularization of mouse corneas. 
(A) The corneal neovascularization was examined and photographed on day 6 after pellet 
implantation (~ 20× magnification of the mouse eye; spots encircle the area of the implanted 
pellet). Corneal neovascularization in spongistatin 1-treated animals was markedly reduced 
compared to vehicle-treated control animals. (B) Angiogenic responses were measured as clock 
hours and vessel length of neovascularization. Bars, the mean ± S.D.M., *p<0.05, student’s      
t-test. 
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10 The Influence of Spongistatin 1 on Endothelial Signaling 
10.1 Kinome Array (PepChip) 
PepChip analysis was performed with spongistatin 1-, vinblastine-, and CA4P-treated 
HUVECs, to investigate specific spongistatin 1-induced and ‘general microtubules’ effects of 
tubulin antagonists on overall signaling in a cellular context. All kinases, which showed 
significantly reduced activity in spongistatin 1-treated cells, are summarized in Table V.2. 
The table also shows the kinases inhibited by vinblastine and CA4P, but only those which 
have been inhibited by all three tubulin antagonists. The activities of kinases were expressed 
as percentage of the activity in untreated cells. Special attention was given to kinases of 
signal transduction pathways, which are prominent in cellular communication and survival.  
Interestingly, inhibition of c-src activity was only detected in PepChip-analysis of   
spongistatin 1-treated cells and not in vinblastine, or CA4P-stimulated HUVEC. Thus, effects 
on c-src phosphorylation activity might be specific for spongistatin 1. In contrast, the 
phosphorylation of AKT, PKC isoforms, and CK2 downstream targets was reduced by all 
investigated tubulin antagonists, arguing for an effect occurring whenever microtubules are 
inhibited. CK2 is a protein involved in cell survival. Effects on this kinase may be therefore 
unspecific response to the exposure to cytotoxic compounds (88). The inhibition of AKT 
phosphorylation activity by spongistatin 1 in PepChip analysis may confirm the previous 
findings of reduced AKT phosphorylation induced by spongistatin 1 (III 6.2 Proliferative 
Signaling: Spongistatin 1 Inhibits AKT-Phosphorylation). The activity of PKC isoforms under 
treatment with spongistatin 1 were investigated in more detail, since the importance of PKC 
isoforms PKC α, δ, and ε, in angiogenesis has been described previously (64-66).  
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Table V.2 Impact of spongistatin 1, vinblastine, and CA4P on kinases. 
The table shows kinases (first column) with significantly reduced activity in HUVECs which 
were treated with the respective compound in comparison to control cells (second column, 
values are percentage of the activity of the respective kinase in untreated cells) and the 
standard error of the measurement (third column). The protein identification number of the 
phosphorylated substrate is given in the column entitled ‘Substrate protein’. Further the 
cellular context of the phosphorylation event is given in the last column. The data of 
vinblastine and CA4P-treated HUVECs show only the kinases, which are inhibited by all 
three tubulin antagonists. 
 
Kinase Spongistatin 1  S.E.M. Substrate protein Cellular context 
AKT1 0.0 0.03 NP_005195 Signaling 
CK2 0.1 0.03 NP_002961 Metabolism 
EGFR, c-src 0.3 0.03 NP_008819 Signaling 
c-src 0.4 0.05 NP_001703 Immunity 
CK2α 0.5 0.02 NP_003753 Transport 
PKC 0.6 0.03 NP_000015 Signaling 
PAK1 0.6 0.01 NP_000116 Transcription 
Kinase Vinblastine S.E.M. Substrate protein Cellular context 
PKCζ 0.3 0.03 NP_003395 Signaling 
PKC 0.4 0.02 NP_004753 Signaling 
PKC 0.4 0.03 NP_001984 Signaling 
CK2α_1 0.4 0.01 NP_005339 Transcription 
PKA; PKCα 0.4 0.03 NP_004812 Protein synthesis 
AKT1 0.4 0.04 NP_003001 Protein synthesis 
CK2 0.5 0.03 NP_008819 Signaling 
PKC 0.7 0.04 NP_001610 Signaling 
Kinase CA4P S.E.M. Substrate protein Cellular context 
AKT1 0.0 0.00 NP_001220 Apoptosis 
PKC 0.5 0.04 NP_004753 Signaling 
PKA; PKCα 0.5 0.04 NP_004812 Transcription 
CK2 0.5 0.04 NP_009028 Signaling 
 
 
10.2 The Influence of Spongistatin 1 on PKC Activity 
10.2.1 Spongistatin 1 Inhibits the Phosphorylation of Distinct PKC Substrates 
To validate the PepChip findings of reduced PKC activity by spongistatin 1, Western blot 
analysis on the phosphorylation of serine residues of PKC-substrates was performed. PKC 
are serine/threonine-specific kinases, however the majority of PKC substrates are serine 
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residues (89). The phosphorylation motifs of PKC phosphorylation substrates are very 
similar, thus it was possible to develop an antibody, detecting many different PKC substrates 
independent of the upstream PKC isoform (90). Employing this antibody in Western blot 
analysis is supposed to provide information on overall PKC activity. 
In control cells, different bands of PKC substrates, which were phosphorylated at their serine 
residues, could be detected. Incubation with the well established kinase inhibitor 
staurosporine (100 nM, 30 minutes), which is known to inhibit PKC activity by binding to the 
ATP-site, caused complete inhibition of PKC-substrate phosphorylation, whereas 
spongistatin 1 (5.0 nM, 30 minutes) reduced phosphorylation not of all, but of distinct PKC-
substrates. This indicates that spongistatin 1 might inhibit a specific PKC isoform         
(Figure V.18).  
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Figure V.18 Spongistatin 1 inhibits phosphorylation of distinct PKC substrates. 
In Western blot analysis of untreated HUVECs (control), bands of phosphorylated PKC-
substrates could be detected. Incubation with staurosporine (stauro), a strong kinase inhibitor, 
completely abolished phosphorylation of PKC-substrates. In contrast, treatment with 
spongistatin 1 caused reduced phosphorylation only of distinct PKC substrates (arrows). 
Detection of β-actin proved equality of protein amounts. 
 
10.2.2 Spongistatin 1 Has no Impact on PKC Activity In Vitro 
The catalytically active centers of PKC isoforms are structurally very similar and selective 
inhibition is therefore quite unlikely. In fact, employing spongistatin 1 in PKC in vitro activity 
assays revealed no direct inhibitory effect on analyzed PKC isoforms α, βI, βII, δ, ε, or ζ 
(Figure V.19). Thus, there must be another mechanism, by which spongistatin 1 affects PKC 
activity. The PKC in vitro assay was performed by Dr. Johann Hofmann, Division of Medical 
Biochemistry, Innsbruck Medical University, Austria. 
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Figure V.19 Spongistatin 1 does not influence PKC activity in vitro. 
PKC in vitro activity assay revealed that spongistatin 1 has no significant influence on the 
activity of PKC isoforms α, βI, βII, δ, ε, and ζ. For PKC isoforms α, βI, δ, and ζ 100 nM 
spongistatin 1 were employed, whereas for PKC βII and ε 50 nM spongistatin 1 were used. Bars, 
the mean ± S.E.M., p>0.05, Rank On Sum-test. 
 
10.3 The Influence of Spongistatin 1 on PKC-Translocation 
Since most of the PKC isoforms, conventional as well as novel, have to be translocated from 
the cytoplasm to membranes for activation, spongistatin 1 may inhibit the activity of specific 
PKC isoforms via disruption of its transport to membranes. Endothelial cell lysates were 
fractionated into a membranous fraction, containing the cytoplasmic membrane and all 
intracellular membranes, and a cytosolic fraction by ultracentrifugation. Detection and 
quantification of different PKC isoforms in both fractions was used to analyze translocation of 
these proteins.  
 
10.3.1 PKC Expression in HUVECs 
Prior to investigations on spongistatin 1 and its effects on PKC activity in endothelial cells, 
the expression of the several PKC isoforms in HUVECs was analyzed by Western blot of 
membrane/cytoplasm fractions. The PKC isoforms α, δ, ε, η, and ζ could be detected. Further 
it could be shown, that except of PKCζ, the translocation of all these proteins to the 
membrane-site can be stimulated with PMA (10 nM, 2 hours). 
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Figure V.20 Expression of PKC isoforms in endothelial cells. 
The expression of diverse PKC isoforms in endothelial cells was investigated via Western blot 
analysis of membrane/cytoplasm fractions. PKC isoforms α, δ, ε, η, and ζ could be detected. 
Aside from PKCζ, the translocation of all detectable PKC proteins to membrane was induced by 
PMA (10 nM, 2 hours). 
 
10.3.2 The Translocation of PKCα is reduced by Spongistatin 1-Treatment 
Since PKCα, δ, and ε are of particular importance for angiogenesis, the effects of 
spongistatin 1 on these three PKC isoforms were investigated in more detail. PKC 
translocation was induced with 10 nM PMA for 2 hours. Pre-incubation with spongistatin 1 
(5.0 nM, 30 minutes) prior to PMA-stimulation resulted in reduced transport of PKCα to 
membranes. Accordingly, an enrichment of PKCα in the cytoplasm was observed. In 
contrast, the translocation of PKCδ and ε were not significantly affected by spongistatin 1 
(Figure V.21 A). Quantitative analysis of Western blots of PKC isoforms after 
membrane/cytosol fractionation proved the visual impressions from Western blot analysis 
(Figure V.21 B).  
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Figure V.21 Spongistatin 1 specifically inhibits the translocation of PKCα. 
(A) Detection of the PKC-isoforms α, δ, and ε in membranous and cytoplasmic fractions of 
HUVECs that were  either stimulated with 10 nM PMA for 2 hours (PMA), or pre-incubated with 
5 nM spongistatin 1 prior to PMA-stimulus (SP1). Detection of VE-cadherin (VEC) and β-actin 
proved purity of the fractions, and the equality of protein amounts. (B) Quantification of PKC 
isoforms in the membrane fraction: the PKC-isoform α is specifically reduced to half by 
spongistatin 1, whereas PKCδ and PKCε were not significantly affected. Bars, the mean            
± S.E.M., *p<0.05, n.s., not significant, Rank On Sum-test. 
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1 Spongistatin 1 is a Powerful Experimental Compound against 
Pancreatic Tumor Progression and Metastasis 
Pancreatic cancer is still a severe disease with poor prognosis, in respect of advanced tumor 
progression and metastasis at the time point of diagnosis. Thus, elucidation of new 
anticancer drugs is required to improve chemotherapy inoperable advanced cases (13-15). 
Intraperitoneal application of spongistatin 1 at the very low dose of 10 µg/kg body weight in 
an orthotopic in vivo model significantly reduced pancreatic tumor growth. Moreover, 
spongistatin 1 remarkably abrogated metastatic activity, which is in line with reduced activity 
of MMP-9 in tumor tissue of mice treated with spongistatin 1. The reduction of metastasis by 
spongistatin 1 is of particular importantance, as 90% of all cancer death arise from the 
metastatic spread of primary tumors (91, 92). In contrast to other cytotoxic compounds 
examined in the same experimental model (93-95), spongistatin 1 seems to be tolerated 
quite well as no influence on the overall body weight of the mice has been observed. Thus, 
spongistatin 1 can be regarded as a powerful experimental agent to combat pancreatic 
tumors.  
 
 
2 The Impact of Spongistatin 1 on Hypoxia Signaling 
HIF-1α expression has been detected in the majority of solid tumors, including brain, bladder, 
breast, colon, ovarian, renal, prostate, and pancreatic cancers. Clinically, HIF-1α 
overexpression is a marker for the highly aggressive disease and has been associated with 
poor prognosis, whereas the loss of HIF-1 activity dramatically decreases tumor growth, 
vascularization, and energy metabolism. Thus, the inhibition of HIF-1/HIF-1α has become a 
very promising approach in cancer therapy (83, 96, 97).  
Since the inhibition of HIF-1 has gained clinical relevance and tubulin-inhibiting drugs, both 
the stabilizing as well as the disassembling types, have been shown to diminish HIF-1α 
stabilization in vitro (98, 99), it seemed to be most promising to investigate effects of 
spongistatin 1 on HIF-1 in the pancreatic tumor model. Indeed, spongistatin 1 was able to 
reduce HIF-1α-levels in vitro in L3.6pl pancreatic tumor cells. However, molecular analysis of 
tumor tissues revealed no impact of spongistatin 1 on HIF-1 activity in vivo. This finding is 
well corresponding with the fact that until now only specific HIF-1 inhibitors were able to 
reduce HIF-1-activity in vivo - although many cytotoxic compounds were described to inhibit 
HIF-1α stability in vitro (83). Thus, the clinical relevance of anti-HIF-1α effects of tubulin 
VI DISCUSSION 
 80 
antagonists in vitro is quite doubtful and seems to be a phenomenon of an unspecific stress 
response rather than of specific anti-HIF-1 activity.  
 
 
3 Reduction of MMP-9 Levels by Spongistatin 1 in Vivo 
3.1.1 The Relevance of MMP-9 in Pancreatic Cancer 
MMP-dependent remodeling of the tumor microenvironment and ECM through lysis of matrix 
proteins is a necessary step in local invasion and metastasis (100-103). In pancreatic cancer, 
the up-regulation of MMPs, especially of the gelatinases MMP-2 and MMP-9, is shown to 
correlate with invasiveness and metastatic potential, and application of MMP-inhibitors has 
shown benefit for patients in clinical trials (104, 105). Additionally, the application of the MMP 
inhibitor BB-94 imparted a survival advantage in the treated animals in an orthotopic nude 
mouse model, similar to the model in the present study (106). 
The highly metastatic L3.6pl carcinoma in the orthotopic tumor model strongly expressed 
MMP-9. Treatment with spongistatin 1 resulted in a significant reduction of MMP-9 mRNA 
and protein levels in comparison to control mice. In fact, MMP-2 is also expressed, but in 
marginal amounts and a compensatory up-regulation of MMP-2 in the spongistatin 1-treated 
group could not be observed. Thus, the reduction of MMP-9 may contribute to the inhibitory 
effects of spongistatin 1 on tumor growth and metastasis. 
 
3.1.2 Reduction of MMP-9 mRNA Levels by Spongistatin 1 
The secretion of MMPs into the extracellular space is a microtubule-dependent process and 
can be disrupted by microtubule-inhibiting compounds (107). However, a reduction of MMP 
mRNA levels by tubulin antagonists has not been described before. Spongistatin 1 reduced 
mRNA levels of MMP-9, but not of VEGF, suggesting selectivity for MMP-9 mRNA. Whether 
this reduction is a matter of a diminished transcription of the MMP-9 gene, or of a 
destabilization of MMP-9 mRNA is not clear.  
Recently, it was described that destruction of microtubules leads to a reduced mRNA 
expression of VEGFR2. The authors have shown the tubulin antagonist nocodazole to inhibit 
the transcription factor Sp1, and thereby reducing the transcription of VEGFR2 (108). Since 
the MMP-9 promoter region contains consensus sequences for the transcription factors Sp1, 
Ap1, and NFκB (109), spongistatin 1 may act in a similar way on the transcritpion of the 
MMP-9 gene. EMSA-studies revealed no differences in the DNA-binding activity of any of 
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these transcription factors in both treatment groups (data not shown). This may argue for 
spongistatin 1 acting on the stability of MMP-9 mRNA, rather than on its transcription. 
However, it must be regarded that the time point of investigation may be a crucial factor in 
this context, since tumors were in a very late progression state at necropsy, and DNA-
binding activities of transcription factors may be no longer detectable. Further studies are 
necessary to uncover the mechanism by which spongistatin 1 acts on MMP-9 mRNA levels. 
These investigations would be of relevance, since findings may provide a new mechanism by 
which tubulin antagonist act on tumor progression and metastasis, but the fact that L3.6pl 
cells do not express MMP-9 in vitro (own observations) complicates continuative studies in 
the pancreatic tumor model. 
 
 
4 Antiangiogenic Action of Spongistatin 1 and the Underlying 
Mechanisms 
4.1 Spongistatin 1 Exerts strong Antiangiogenic Action In Vitro and In Vivo 
Since the inhibition of angiogenesis gains more and more relevance in cancer therapy, there 
is an increasing demand for appropriate drugs. Microtubule-targeting drugs belong to the 
most potent antiangiogenic compounds, but they also suffer from toxic-side effects. Thus, 
new tubulin-binding compounds with fewer side effects are currently being sought after (18). 
Spongistatin 1 disrupts microtubules via binding to a specific site on β-tubulin. The 
uniqueness of this site may add therapeutic qualities to spongistatin 1, making it worthwhile 
to investigate the antiangiogenic potency of this compound. 
Spongistatin 1 inhibited angiogenesis in vitro and in vivo at extremely low concentrations, far 
below toxic doses. Further, inhibition of angiogenesis by spongistatin 1 occurred at 
concentrations beneath that of the established tubulin antagonists including vinblastine, 
paclitaxel, and the new promising compound CA4P. Moreover, proliferating endothelial cells 
were particularly sensitive to spongistatin 1, since proliferation was inhibited at a 
concentration as low as 100 pM. In cytotoxicity measurements, non-proliferating HUVECs 
tolerated more than 10-fold higher concentrations of spongistatin 1 than proliferating cells, 
arguing for a specific action on newly developing vessels. Additionally, applicated 
intraperitoneally, spongistatin 1 inhibited neovascularization in vivo. This indicates the 
drugability of spongistatin 1. Summing up, spongistatin 1 is a potent antiangiogenic 
compound exhibiting many qualities that support its use in therapeutic applications. 
 
VI DISCUSSION 
 82 
4.2  Inhibition of Endothelial Proliferation 
4.2.1 Spongistatin 1 Particularly Affects Endothelial Proliferation 
Spongistatin 1 exerted a particularly high impact on proliferating endothelial cells. It is not 
clear where the sensitivity of proliferating cells towards spongsitatin 1 comes from and why 
the other tubulin-inhibiting drugs, vinblastine, paclitaxel, or CA4P were not that effective on 
proliferating cells. Potentially the strong effect of spongistatin 1 derives from its ability to bind 
to a unique site at β-tubulin. Furthermore, there might be significant differences in drug-
uptake, leading to an enhanced incorporation of spongistatin 1 in proliferating cells. 
Interestingly, spongistatin 1 was the only tubulin antagonist inhibiting c-src and thereby 
reducing the activating phosphorylation of CEACAM-1 (NP_001703) in the kinome array. 
This receptor was recently shown to be involved in proliferation and to be expressed only on 
proliferating endothelial cells, especially during tumor angiogenesis. This selectivity for 
tumor-induced angiogenesis turned CEACAM-1 out to be a particular attractive target in 
antiangiogenic therapy and might be therefore an interesting aspect in antiangiogenic action 
of spongistatin 1 (110-112). However, further studies are necessary to reveal the influence of 
spongistatin 1 on c-src and CEACAM-1 activity, and its relevance for antiproliferative effects 
of spongistatin 1. 
 
4.2.2 Mitotic and Non-Mitotic Actions of Spongistatin 1 on Proliferation 
The mechanisms by which spongistatin 1 exerts its antiproliferative effects are not clear at 
all. Of course, the tubulin antagonist spongistatin 1 inhibits mitotic spindle formation as 
shown in the flow cytometric measurements. However, spindle-poisoning effects were 
detected at a concentration as low as 1.0 nM, a 10-fold higher concentration than that which 
inhibits proliferation. Thus, the effects observed have to be interpreted as different from 
simple antimitotic actions. Also acute cytotoxicity can be excluded as the reason for the 
strong impact of spongistatin 1, since significant reduction of cell viability in the CellTiter 
BlueTM assay occurred at concentrations beginning at 5.0 nM. 
Interestingly, spongistatin 1 inhibited the activating phosphorylation of AKT. The AKT-
dependent pathway is of vital importance in endothelial proliferation since the majority of 
growth factor-induced responses are mediated by the activation of the PI3K/AKT signaling 
cascade (58). Spongistatin 1 might influence proliferation by inhibiting AKT-mediated 
signaling. Thus, spongistatin 1 seems to act on proliferation by both the inhibition of mitotic 
spindle formation and by the disruption of the proliferative signaling pathways in the 
interphase. 
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4.3 Directed Migration 
Intercellular coordination and cellular motility are associated with the microtubule-skeleton 
and are basic elements of directed migration and the formation of tubes. In line with these 
facts, spongistatin 1 inhibited both processes. Moreover, employing spongistatin 1 in 
migration and chemotaxis assays elucidated several aspects of the role of microtubules in 
directional migration in endothelial cells. 
 
4.3.1 Microtubules Do Not Contribute to the Migration Force in Endothelial Cells 
The influence of microtubules on migration is cell type-dependent. Migration is unaffected in 
fish keratocytes or even enhanced in neutrophils, when microtubules are disrupted (29, 30). 
However, in most cell types, including endothelial cells, the breakdown of the microtubule 
network correlates with motility impairments. Microtubules may be involved directly in the 
generation of protrusive forces, since the plus ends of growing microtubules generate a force 
of several pN, which is enough to deform lipid bilayers (37). Spongistatin 1-treated 
endothelial cells were not reduced in accumulative migration distance or velocity in the 
chemotaxis assay, suggesting that the tractive force of the cells is not affected by 
spongistatin 1-induced inhibition of the microtubules. Hence, the main force of cell movement 
seems to be generated by the actin-cytoskeleton, whereas the contribution of microtubules to 
traction in endothelial cells is negligible. Antimigratory effects in endothelial cells caused by 
the inhibition of the microtubules have been demonstrated before. However, this work clearly 
demonstrates that the microtubule-inhibiting compound spognistatin 1 does not act by 
inhibition of tractive forces. 
 
4.3.2 Microtubules and the Intracellular Polarization 
Given that microtubules do not contribute to tractional forces in endothelial cells, the 
inhibitory mechanism of spongistatin 1 on endothelial migration remains to be elucidated. 
The morphological changes endothelial cells are undergoing upon spongistatin 1 treatment, 
including cell rounding, dearrangement of mitochondria and the disorientation of F-actin 
arrangement suggest that spongistatin 1 inhibits polarization of the cell and thereby prohibits 
directed cell migration. These suggestions are well in line with findings that microtubules are 
essential for the generation and maintenance of cellular polarity in fibroblasts. Disassembly 
of microtubules in these cells results in loss of polarization and the ability of directional 
migration (40). However, the molecular processes underlying the affection of cellular polarity 
by tubulin antagonism are still unclear.  
 
VI DISCUSSION 
 84 
4.4 How Microtubules May Control Polarization 
How does the disassembly of microtubules inhibit cellular polarization? The generation and 
maintenance of cellular polarity is an interplay of several factors including sensoring and 
regulatory elements (PI3K, small RhoGTPases) and the cytoskeleton (actin-filaments, 
microtubules, motorproteins). These factors are generating a system of interlinked modules, 
which regulate each others functionality depending on negative and positive feedback loops. 
Thus, the inhibition of the module ‘microtubules’, is likely to interfere with the functionality of 
other modules in the polarization system. Investigation of the effects of spongistatin 1 on 
directional migration raised several evidences of which elements might be affected, as 
discussed in the following. 
 
4.4.1 The Small RhoGTPases 
During migration, highly coordinated processes between actin and microtubules are taking 
place and both affect each others dynamics through the regulation of the small Rho 
GTPases RhoA, Cdc42, and Rac1 (113-115). The linkage of microtubules and actin, as well 
as the fact that spongistatin 1-treatment affects F-actin arrangement indicates that the 
functionality of small RhoGTPases is influenced upon the disassembly of microtubules.  
RhoA is regulating contractile forces during migration. Since the overall cellular movement 
was not inhibited by spongistatin 1, it seems to be unlikely that the activity of RhoA was 
affected. Further, the group of Omelchenko et al. shows that microtubular control of polarity 
is independent of RhoA-mediated contractility in fibroblasts (116). 
Cdc42 is involved in microtubules plus end capture and their stabilization at the leading 
edge. Additionally, Cdc42 is responsible for MTOC orientation (48, 117). It has been 
discussed whether dynein is implicated in centering the MTOC, as it can pull the plus ends of 
cortically attached microtubules (118). The present study shows that the orientation of the 
MTOC was not inhibited upon spongistatin 1-treatment. Even when microtubules were 
completely depolymerized, the MTOC was still orientated to the leading edge and the cell 
moved into the direction provided by the MTOC. It has been reported that vinblastine inhibits 
Cdc42-activity in endothelial cells (119). Thus, either the Cdc42-function of orientateting the 
MTOC is not affected by spongistatin 1, as it this function of Cdc42 is microtubule-
independent or the MTOC-orientation in random-migration is independent of Cdc42. 
Rac1 is localized at the leading edge of migrating cells and promotes the formation of the 
lamellipodium by inducing the polymerization of F-actin. Treatment with spongistatin 1 did not 
abrogate lamellipodia formation, but their number was reduced. It was shown that Rac1 and 
microtubules are activating each other in a reciprocal manner. Rac1-activating protein 
IQGAP1 binds to CLIP170 which in turn binds to the plus ends of the growing microtubules 
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(120). Further, the guanine nucleotide exchange factors Trio, GEF-H1, and Asef, which 
activates Rac1 by substituting GDP to GTP, are shown to be microtubule-associated (40, 
121-123). Besides, the group of Bijman et al. could show vinblastine-mediated inhibition of 
Rac1 in endothelial cells (119). Thus, the inhibition of microtubules by spongistatin 1 may 
reduce Rac1 activation at the leading edge. 
 
4.4.2 Effects on PI3K 
The elementary importance of PI3K for chemotactic migration has been elucidated in very 
recent works. In this context, it was shown that the PI3K/AKT pathway promotes 
microtubules stabilization in migrating fibroblasts and endothelial cells, which in turn might 
promote Rac1 activity. Further, it has been shown that the activity of Rac1 and AKT are 
interlinked by a positive feedback loop, although it is not yet clear, whether Rac1 is activated 
by AKT downstream of PI3K or vice versa (124-127). The inhibition of AKT-phosphorylation 
by spongistatin 1 may be symptomatic for effects of microtubule-disassembly on PI3K-
depending signaling. The interference with PI3K/AKT-signaling and the reduction in 
directionality and formation of lamellipodia upon spongistatin 1-treatment implicates that 
microtubules are the connection between PI3K/AKT and Rac1-dependet actin organization 
and breaking this linkage by tubulin-inhibiting drugs abrogates directional migration. 
 
 
5 Microtubules in Endothelial Signaling 
5.1 Tubulin Antagonists Inhibit AKT, CK2, and PKC isoforms 
To gain more insights on the global effects of spongistatin 1 on cellular signaling in special 
and microtubule-inhibiting drugs in general, a kinome array with tubulin antagonist-treated 
HUVECs was performed. The advantage of this array in comparison to conventional in vitro 
kinase activity screenings is that the impact of a compound can be investigated on the 
overall kinase activity in the cellular context, and therefore both the direct and indirect actions 
of the respective compound on kinase activity can be detected (cf. PepChip data and PKC in 
vitro assay). The array was supposed to reveal influences of tubulin antagonism on signaling 
pathways with relevance in angiogenesis and thereby identify new mechanisms by which 
tubulin antagonists act. 
In the kinome array, three kinases were affected in their activity by all three tested tubulin 
antagonists: CK2, AKT, and PKC isoforms. CK2 is mainly involved in cell survival and may 
be unspecifically affected by cytotoxic drugs (88). However, CK2 seems also to be a 
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microtubules-associated protein, promoting the stabilization of microtubules (128). This might 
explain why all three tubulin binding-drugs affect CK2. 
The importance of AKT-signaling in angiogenesis has been discussed in forgoing sections of 
this work. Tubulin antagonist-induced reduction of AKT-activity in the kinome array is well 
corresponding with reduced phosphorylation of AKT by spongistatin 1, and previous reports 
of tubulin-targeting drugs inhibiting AKT phosphorylation in endothelial cells (129, 130). 
Further studies on the underlying mechanisms of tubulin antagonist-mediated inhibition of 
AKT might be quite interesting. However such studies would not provide the discovery of a 
new, unknown mechanism of tubulin antagonism. 
Thus, ongoing investigations of the impact of spongistatin 1 on PKC activity were most 
promising, since the close relationship of PKC signaling and angiogenesis has been 
described previously. The repeated appearance of reduced PKC activity upon incubation 
with spongistatin 1, vinblastine, and CA4P, indicates that effects on PKC-signaling may 
provide a general mechanism by which tubulin antagonists act on angiogenesis. 
 
5.2 PKCα Translocation Depends on Functional Microtubules in Endothelial Cells 
Analysis of spongistatin 1 on PKC activity has shown a rapid and selective impact on PKC 
isoform α. However, spongistatin 1 does not inhibit PKCα directly, since PKCα activity was 
not inhibited in the PKC in vitro assay. Rather, the translocation and therefore the activation 
of PKCα is disrupted by spongistatin 1. Similar effects could be observed when treating cells 
with vinblastine (data not shown). Thus, it can be assumed that inhibition of PKCα-
translocation is not a spongistatin 1-specific phenomenom but relies on the disassembly of 
microtubules. These findings are well in line with findings of microtubule-dependent PKCα-
translocation in neurons and smooth muscle cells (131, 132). However, the present study 
shows for the very first time the microtubule-dependency of PKCα-translocation in 
endothelial cells. 
Previous work on knock-down and over-expression of PKCα in endothelial cells has clearly 
shown that PKCα is essential for angiogenesis: migration and cord formation are inhibited by 
PKCα knock-down, whereas PKCα over-expression results in increased proliferation, 
migration, and tube formation (133-135). Anti-sense RNA-studies on PKCα revealed that 
endothelial cells are not able to adhere to an extracellular matrix (134). Further, it is known 
that VEGF-induced proliferation requires PKCα (133), and it has been shown that PMA-
induced angiogenesis is depending on PKCα activity (136). 
All these studies have demonstrated the elementary importance of PKCα in angiogenesis. 
Hence, inhibition of interphase microtubules by tubulin antagonists and subsequently 
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reduced PKCα-translocation may provide a new mechanism by which tubulin antagonists act 
on angiogenesis. 
 
5.3 Microtubule-Inhibiting Drugs Disrupt Translocation Processes 
Spongistatin 1 inhibits the translocation of PKCα to the membrane. Furthermore, the 
activating phosphorylation of AKT, which is also a process depending on translocation to 
membrane, is reduced by spongistatin 1. Additionally, the activity of c-src has been shown to 
be microtubule-associated and to depend on translocation (137) and is inhibited by 
spongistatin 1 in the kinome array. In contrast, spongistatin 1 has no inhibitory effects on 
ERK1/2 phosphorylation. ERK and other MAPK are organized in huge protein complexes 
which are assembled by scaffold proteins. Thus, kinases of the cascade are in spatial 
closeness which makes translocation processes unnecessary. This might explain why 
spongistatin 1 had no impact. However, this finding also confirms the suggestion that the 
inhibition of microtubules disrupts several signaling pathways in endothelial cells by inhibition 
of translocation processes. 
 
 
6 Conclusions 
6.1 Anticancer Activities of Spongistatin 1 
This work presents the marine compound spongistatin 1 as a promising agent in the combat 
against cancer, since spongistatin 1 inhibits pancreatic tumor progression and metastasis in 
vivo. The reduction of MMP-9 levels by spongistatin 1 might be involved in antimetastatic 
effects and more over, potentially presents a novel mechanism by which tubulin antagonists 
inhibit tumor progression and metastasis.  
Investigations of tumor tissues and of spongistatin 1 effects on pancreatic cancer cells in 
vitro also exhibited the difficulties of the transferation of in vitro effects to in vivo models and 
vica verse. Thus, inhibitory effects of HIF-1α in vitro could not be observed in the tumor 
model. In contrast, underlying mechanisms of the reduction of MMP-9 levels by spongistatin 
1 in vivo could not be further investigated, since the cancer cell line does not express MMP-9 
in vitro.  
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6.2 Non-Mitotic Action of Tubulin Antagonist on Angiogenesis 
Spongistatin 1 exerts strong antiangiogenic effects both in vitro and in vivo. Importantly, 
spongistatin 1 was even more potent in angiogenic in vitro assays than the established 
tubulin antagonists vinblastine, CA4P, and paclitaxel. Moreover, molecular analysis of the 
mechanisms of spongistatin 1 shed light on the still poorly understood antiangiogenic action 
of tubulin antagonism. Detailed analysis of spongistatin 1 effects on endothelial cell 
morphology, organelle arrangement, directionality, cytoskeleton, and signaling pathways 
facilitates the creation of a model of the non-mitotic effects of tubulin antagonists on 
angiogenesis. 
 
6.2.1 The Importance of Cellular Polarization in Vessel Formation 
Treatment with spongistatin 1 abrogates directed migration by inhibition of the intrinsic 
polarity in endothelial cells. Spongistatin 1 most likely acts by interrupting the connection 
between the chemo-attractive sensing elements (PI3K/AKT) and the migratory apparatus   
(F-actin). Polarization of the cell is not only the first step in the process of directed migration, 
but a fundamental process throughout the whole vessel formation. First, the tip cell has to 
establish an intrinsic polarization to form filopodia for sensing chemo-attractive signals and to 
form one leading edge to guide the tailing stalk cells. Secondly, the stalk cells need to 
polarize to distinguish between the direction of the tip cell (front), and the direction of the 
parent vessel (back). Finally, the completed vessel develops an apical (towards the vessel 
lumen) and a basal face (towards the vessel wall) of the endothelium depending on an 
intrinsic polarity (59, 138). Thus, inhibition of cellular polarization by the depolymerization of 
the microtubules has a global impact on vessel formation. 
 
6.2.2 Microtubule-Inhibiting Drugs Affect Multiple Signaling Pathways 
The impact of functional microtubules on endothelial signaling is not very well characterized, 
since the contribution of microtubules to cell signaling is extremely cell type-specific: 
signaling pathways vary in different cell types and translocation processes also occur along 
actin filaments. Additionally, due to the cellular morphology or intracellular organization, 
translocation processes are not always necessary. Endothelial cells are very large and flat 
cells, and are therefore depending on bridging long distances in signaling transduction. Thus, 
it can be assumed that in endothelial cells several signaling pathways require translocation 
processes. As it was shown for PKCα, many of these translocation processes most likely 
depend on functional microtubules. Consequently, the disassembly of microtubules affects 
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not only one but several signaling pathways. Moreover, translocation-dependent kinases like 
AKT and PKCα present central signaling nodes with a great number of downstreaming 
signaling pathways. For instance, AKT is able to phosphorylate more than 9000 proteins 
(139).  
Thus, the impact of microtubule-inhibiting compounds like spongistatin 1 on cellular signaling 
resembles the effects of multiple kinase inhibitors. Recent investigations indicate that 
targeting multiple signaling pathways by respective kinase inhibitors, e.g. sunitinib malate or 
sorafenib, improve efficacy of tumor therapies. Especially MAPK, PI3K/AKT, and PKC are in 
the focus if interest, since these kinases represent integrative nodes of growth factor 
signaling (140, 141). Thus, multi kinase inhibiting qualities are most likely to be involved in 
the strong antiangiogenic action of tubulin antagonists. 
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SUMMARY 
 
A In Vivo Effects of the Anticancer Compound Spongistatin 1 
The marine compound spongistatin 1 disrupts microtubules by binding to a specific site at   
β-tubulin. Microtubule-inhibiting drugs belong to a very successful class of anticancer 
compounds, and also spongistatin 1 has shown strong anticancer properties in previous      
in vitro studies. Based on this pronounced antitumor efficacy, we investigated the 
chemotherapeutic potential of spongistatin 1 in vivo in an orthotopic pancreatic tumor model. 
Spongistatin 1 strongly inhibited tumor progression, as judged by tumor volume and tumor 
weight. Moreover, incidences of metastases in liver, regional lymph nodes and peritoneum 
were dramatically reduced by spongistatin 1. Molecular analysis of tumor tissues revealed 
the mRNA and protein levels of matrix metalloproteinase 9 to be significantly lower in 
spongistatin 1-treated mice than in control animals, which is well in line with inhibition of 
tumor progression and metastasis. Thus, spongistatin 1 seems to be a powerful experimental 
drug in combating cancer. 
 
B The Antiangiogenic Potential of Spongistatin 1 
Besides their application as classical chemotherapeutics, microtubule-inhibiting drugs have 
been shown to be very potent in antiangiogenic therapy, which promted us to investigate the 
antiangiogenic potential of spongistatin 1. In angiogenic in vitro assays, spongistatin 1 
inhibited endothelial proliferation, migration and tube formation at non-toxic concentrations. 
Most importantly, spongistatin 1 was even more potent than the well-known tubulin 
antagonists vinblastine, CA4P, and paclitaxel. In the mouse cornea pocket assay, the 
antiangiogenic effects of spongistatin 1 were investigated in vivo. Application of    
spongistatin 1 into the intraperitoneum significantly reduced growth factor-induced 
neovascularization of mouse corneas. Thus, spongistatin 1 has been demonstrated to 
effectively inhibit angiogenesis in vitro and in vivo. 
Since it has been reported that the affection of interphase microtubules plays an important 
role in the antiangiogenic action of tubulin antagonists, non-mitotic effects of    spongistatin 1 
were investigated in order to elucidate the underlying mechanisms of its antiangiogenic 
effects. Employing spongistatin 1 in a chemotaxis assay has shown that endothelial 
migration is not inhibited by affection of the cellular motility itself, but rather by reduction of 
the directionality of endothelial cells. Life-cell imaging of GFP-tubulin transfected cells 
demonstrated that spongistatin 1 has no effect on the orientation of the MTOC towards the 
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leading edge, which is a crucial factor in directed migration. In contrast, spongistatin 1-
induced de-arrangement of F-actin seems to be involved in the inhibition of endothelial 
directionality. 
To get further insights into the effects of spongistatin 1 on angiogenic cell signaling, a kinome 
array with spongistatin 1-treated HUVECs was performed. Interestingly, spongistatin 1 
reduced the activity of PKC. Continuative investigations have further shown that   
spongistatin 1 affects the phosphorylation of certain PKC substrates, indicating that the 
impact of spongistatin 1 might be PKC isoform-specific. PKC in vitro assay did not reveal any 
direct inhibition of PKC isoforms α, βI, βII, δ, ε, or ζ by spongistatin 1, but we could show that 
the translocation of PKCα from the cytosol to the membrane is reduced. Since the 
translocation of PKCα to the membrane is essential for its activation, and PKCα is an 
important factor in angiogenesis, the reduction of its translocation is likely to contribute to 
antiangiogenic effects of spongistatin 1. Moreover, this might provide a new general 
mechanism of tubulin antagonism in angiogenesis, since the activity of PKC isoforms in the 
kinome array was also reduced in vinblastine and CA4P-treated cells. 
 
In summary, this work presents the marine compound spongistatin 1 as a promising agent in 
the combat against cancer, since it inhibited pancreatic tumor progression and metastasis   
in vivo and exerted strong antiangiogenic effects in vitro and in vivo. Moreover, the 
characterization of underlying mechanisms of the antiangiogenic action of spongistatin 1 
might be prototypic for general tubulin antagonism in angiogenesis. 
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